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In all affairs it is a healthy thing now and then to hang a question mark  
on the things you have long taken for granted. 
-  Bertrand Russell (1872-1970) 
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1 INTRODUCTION  
Protein post-translational modifications (PTMs) are essential regulatory 
mechanisms involved in cellular signal transduction processes and are catalyzed by 
a vast number of enzymes. Alterations in protein PTMs are reflected in 
deregulation of cellular processes, e.g. cell proliferation, gene expression, protein-
protein interaction and apoptosis, which can result in different pathological 
conditions. In this regard, the targeting of deficient enzymes to treat distinct 
diseases has long been a primary goal in the drug discovery field. 
The discovery and development process of a drug can take approximately 15 
years with an investment leastways of $ 1 billion (Hughes et al. 2011). To expedite 
this process, a considerable effort is focused on the improvement of technology to 
produce data of sufficient quantity and quality. The purpose of high throughput 
screening (HTS) assays during the hit discovery process is to diminish the need for 
repetitive manual tasks, and remove the potential errors, with a significant time 
thrift. Nowadays, more than 100 000 compounds can be tested per day using a 
conventional HTS assay (Schneider 2018). 
A variety of sensitive HTS assays have been applied to measure enzyme 
activity using traditionally radiometric methods. Currently, the tendency is for the 
use of luminescence-based systems, as they provide a method that overcome the 
major problems with radiometric assays related to the shelf life of radioligands and 
radioactive waste. These luminescence systems include dual and single label 
assays, with a variety of distinct labels, including organic dyes, biological 
fluorophores and lanthanide probes. Most of the commercially available methods, 
either radiometric or luminometric systems, rely on the use of specific antibodies 
as a detection component. The need for specific antibodies is typically the limiting 
factor for these assays as there is an insufficient range available to target the whole 
PTM spectrum (Li et al. 2008). Antibody-free systems, based on metal ion 
coordination, have been extensively developed for phosphorylation (Loomans et al. 
2003; Shults & Imperiali 2003). However, the nature of this approach has limited 
its expandability to other PTM types. New complex targets for drug discovery are 
constantly emerging, suggesting new versatile HTS technologies are also in 
demand. Sensitive, cost-effective and adaptable HTS methods would provide new 




2 REVIEW OF LITERATURE 
A detection technology which provides a method for assaying a wide variety of 
PTM types in a single platform is referred to here as “universal technology.” A 
universal biochemical PTM enzymatic assay for inhibitor or activator screening 
would use a generic detection component for PTM enzyme activity monitoring. In 
a luminescence-based strategy, the universal variable of the assay, i.e., the 
detection component, has to carry the reporter label, as substrate peptides will 
differ from enzyme to enzyme due to their specificity. Several approaches have 
been proposed following this design, but their development for universal 
applicability has been challenging. In this review of the literature, universal and 
target-specific detection technologies that have been applied to PTM enzymatic 
HTS assays are presented together with a brief introduction of protein PTMs and 
the enzymes involved. Also, a brief introduction about enzymes as therapeutic 
targets for inhibition or activation in different disease treatments is presented. 
2.1 Protein post-translational modifications 
Our human gene set has been estimated at approximately 25,000 genes 
(International Human Genome Sequencing Consortium 2004), while the size of the 
human proteome comprises over 1 million proteoforms (Jensen 2004). This 
diversity is gained after mRNA alternative splicing and is enriched by the PTMs 
increasing also the range of protein function. Protein PTMs are covalent additions 
or proteolytic cleavage events which represent a significant regulatory mechanism 
of the proteome. The modification of single or multiple amino acids defines protein 
function, localization, interaction, turnover, and the tertiary and quaternary 
structures. The occurrence of these events rely on the spatial orientation and 
surrounding of the amino acid (AA), leading to the specificity and selectivity of the 
protein (in a time and signal dependent manner) (Hirano et al. 2016). There are 
more than 300 types of PTMs that yield the highly complex variety of protein 
forms (proteoforms) and diversify protein function (The UniProt Consortium 2015; 
Kim et al. 2016). Statistical analysis of PTM frequency from the Swiss-Prot 
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2 REVIEW OF LITERATURE 
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been proposed following this design, but their development for universal 
applicability has been challenging. In this review of the literature, universal and 
target-specific detection technologies that have been applied to PTM enzymatic 
HTS assays are presented together with a brief introduction of protein PTMs and 
the enzymes involved. Also, a brief introduction about enzymes as therapeutic 
targets for inhibition or activation in different disease treatments is presented. 
2.1 Protein post-translational modifications 
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or proteolytic cleavage events which represent a significant regulatory mechanism 
of the proteome. The modification of single or multiple amino acids defines protein 
function, localization, interaction, turnover, and the tertiary and quaternary 
structures. The occurrence of these events rely on the spatial orientation and 
surrounding of the amino acid (AA), leading to the specificity and selectivity of the 
protein (in a time and signal dependent manner) (Hirano et al. 2016). There are 
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forms (proteoforms) and diversify protein function (The UniProt Consortium 2015; 
Kim et al. 2016). Statistical analysis of PTM frequency from the Swiss-Prot 




database indicates that phosphorylation, acetylation, and glycosylation are the three 
most abundant experimentally identified PTMs (Khoury et al. 2014).  
A protein can be modified by more than one PTM type or by the same PTM at 
different residues. Since PTMs affect the molecular mass of proteins, technologies 
such as mass spectrometry (MS) can provide information regarding identification, 
location and quantity of PTMs (Kim et al. 2006; Aebersold & Mann 2016). The 
expression dynamics of this assortment of PTMs (Figure 1) is catalyzed by 
enzymes. These are called ‘writers’ when they add a certain PTM, such as kinases, 
or ‘erasers’ if they remove,  such as phosphatases (Seet et al. 2006; Lim & Pawson 
2010). Additionally, protein domains called ‘readers’ can modulate signaling 
through PTMs by recognizing them and trigger a cellular response. There is an 
active interplay between writers, erasers and readers that regulates a variety of 
cellular processes. In this sense, the understanding of this interplay is the basis for 
addressing the deregulated biological processes that underline different diseases. In 
the following section, the most common PTMs are briefly described including the 
modular recognition domains and catalytical enzymes. 
 
Phosphorylation is a process that catalyzes the transfer of a phosphate group 
from adenosine triphosphate (ATP) to the acceptor residue, serine, threonine, 
tyrosine (mainly in eukaryotes) and histidine or aspartate (mainly in prokaryotes), 
generating adenosine diphosphate (ADP) (Deribe et al. 2010). Phosphorylation is 
the most studied PTM and was one of the first to be described (Hunter & Cooper 
1985; Pawson 2002). This reversible PTM is regulated by kinases and 
phosphatases, and due to its rapid and transient nature, acts as the primary response 
to stimuli within a cellular process enhancing or depleting enzyme activity 
(Audagnotto & Dal Peraro 2017). 
Every time a phosphoryl group is added to a specific AA residue, a -2 negative 
charge is added to the modified protein, altering its structure and electrostatic 
properties (Deribe et al. 2010). This characteristic of phosphorylation enables 
modulation of the molecular interactions, either facilitating protein-protein 
interactions (PPIs) (Langeberg & Scott 2015) or dissociation (Rubin et al. 2005). 
The phosphorylated residues mediating PPIs are recognized by certain modular 
domains such as the Src Homology 2 (SH2). This domain represents the largest 
class of domains and allows all the SH2-containing proteins to localize 
phosphorylated tyrosine (pTyr) sites and trigger different cellular responses (Flynn 
2001; Beltrao et al. 2013). The specificity of these PPIs derives from the ability of 
the SH2 domains to recognize additional residues surrounding the pTyr of the 
binding site. Structural studies have reported that this specificity can be mediated 





Figure 1. The most common enzymatic post-translational modifications (PTMs) in 
eukaryotes and their amino acid targets. The chemical structures of the 20 amino 
acids together with their chemical symbol, and the most important PTMs occurring 
at each residue are depicted. 
 
Glycosylation is one of the more complex PTM processes, and involves the transfer 
of a glycosyl group from a substrate donor to a protein. Based on the type of 
linkage between the sugar and AA, it is classified in four categories: O-
glycosylation (the sugar is attached with the hydroxyl group of a serine, threonine 
or tyrosine), N-glycosylation (the sugar is attached with the amino group of an 
asparagine), glycosylphosphatidylinositol (GPI) anchors (a GPI is attached to the 
C-terminal of a protein chain), and C-mannosylation (the sugar moiety is attached 
to a carbon on a tryptophan) (Moremen et al. 2012; Krasnova & Wong 2016; 
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Audagnotto & Dal Peraro 2017). The attached glycan (many sugars) can be highly 
complex with multiple different combinations of glycan branching, providing a 
substantial structural diversity (Moremen et al. 2012). The main purpose of this 
glycan diversity is to alter protein thermodynamic and kinetic properties in distinct 
manners to regulate protein stability, aggregation, cell surface interactions, enzyme 
activity and protein trafficking (Hanson et al. 2009; Sun et al. 2016; Audagnotto & 
Dal Peraro 2017). 
 
Acetylation is dynamic PTM that transfers acetyl groups using acetyl coenzyme A 
(acetyl CoA) to the ε-amino group of lysines. Another type of acetylation 
corresponds to the N-terminal (Nt) modification, which occurs at the N-termini of 
the nascent polypeptide chains and proteins (Drazic et al. 2016). Lysine acetylation 
is considered as a reversible PTM, and is catalyzed by lysine acetyltransferases 
(KATs) and regulated by lysine deacetyltransferases (KDACs). Whereas Nt-
acetylation is irreversible and catalyzed by Nt-acetyltransferases (NATs).  
It has been widely reported that lysine acetylation plays an important role in 
chromatin structure regulation and its transcriptional activity (Xu et al. 2014). The 
effect of acetylation on chromatin structure modulation may be due to an 
electrostatic mechanism, since the addition of an acetyl group neutralizes the 
positive lysine charge (Martin & Zhang 2005). Besides the effects of writers and 
erasers modulating cellular functions, modular domains, such as the bromodomain 
reader, a part of certain transcription factors and KATs, can bind to acetylated 
lysine and build large transcriptional and chromatin-remodeling complexes (Seo & 
Lee 2004; Filippakopoulos & Knapp 2012). 
 
Crosstalk between PTMs. Coordination between PTMs is essential for the 
regulation of different cellular pathways (Beltrao et al. 2013). PTM crosstalk can 
create a “code” on the protein surface that is recognized by specific domains 
leading to the activation or inhibition of downstream events (Lothrop et al. 2013). 
A certain PTM code delivers or retains the signal only if the surrounding input is 
present at the same time and place (Yang & Seto 2008; Venne et al. 2014; Yang & 
Qian 2017). PTM crosstalk has been classified into positive and negative events. In 
the positive form, the initial PTM actively triggers either the second PTM or serves 
as an interaction site for other proteins (Hunter 2007; Venne et al. 2014). In the 
negative form, there is direct competition between two PTMs for the same AA or 
an indirect effect when a specific PTM blocks the recognition of the second PTM, 
thus avoiding its addition or removal (Hunter 2007; Beltrao et al. 2013). The 
importance of the interplay between different PTMs relies on the efficient 
coordination between the PTMs, which allow signal translation into functional 
cellular processes. The most common enzymatic PTMs are summarized in Table 1. 
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Table 1.  Most common enzymatic PTMs in eukaryotes and their characteristics and 
functions. 
References provided in the text except where noted. *A single sugar: 203 or a chain: >800. 
εx cannot be P  (Moremen et al. 2012). αIt varies according to the enzyme, with P as 
important AA residue (Moremen et al. 2012). ± (Clarke 2013) Ψ, a hydrophobic residue. µx, 
any AA (Liddy et al. 2013). ƟCAAX: C, Cys; A, an aliphatic AA; x, any AA (Cho & Park 
2016). βGlycine in the N-terminal MGXXXS/T: M, Met; G, Gly; S, Ser; T, Thr; x, any AA (Cho 
& Park 2016). N.D, not determined (Jensen 2006; Kim et al. 2016). 
2.1.1 The role of protein PTMs 
In this section, phosphorylation cascades and crosstalk between distinct PTMs are 
presented to recognize how their interplay affects such functions as protein activity, 
cellular location, and protein interaction. As an example, the downstream signaling 
of the epidermal growth factor receptor (EGFR) kinase is briefly described from its 
initiation till its termination (Figure 2). 














N-Glycosylation >800 N NxS/Tε Protein folding, stability, 
O-Glycosylation 203, 
>800* 
S/T/Y α cellular interaction 
Acetylation 42 K  GK, KP Protein stability, PPIs 
Methylation 14 K/R/H± MK, RGG Transcription, protein-
nucleic acid interactions 
Ubiquitylation >1000 K varies Protein degradation 
SUMOylation 12,000 K ΨKxD/Eµ Subcellular transport 
Neddylation 9072 K varies Protein stability 
Myristoylation 210 G MGxxxS/Tβ Protein localization,  
Farnesylation 204 C CAAxƟ PPIs, protein-
membrane 
Palmitoylation 238 C varies interactions 
Sulfation 80 Y N.D Signalling, protein 
localization, PPIs 
Citrullination <1 R GxRGΨ Protein folding 
Oxidation 16 C/M C/S/TxxC Protein oxidative 
regulation 
Nitration 45 Y N.D Oxidative damage 
Hydroxylation 16 K/P N.D Structural stability 
(collagens) 
Crotonylation 68 K N.D Protein structure 




Audagnotto & Dal Peraro 2017). The attached glycan (many sugars) can be highly 
complex with multiple different combinations of glycan branching, providing a 
substantial structural diversity (Moremen et al. 2012). The main purpose of this 
glycan diversity is to alter protein thermodynamic and kinetic properties in distinct 
manners to regulate protein stability, aggregation, cell surface interactions, enzyme 
activity and protein trafficking (Hanson et al. 2009; Sun et al. 2016; Audagnotto & 
Dal Peraro 2017). 
 
Acetylation is dynamic PTM that transfers acetyl groups using acetyl coenzyme A 
(acetyl CoA) to the ε-amino group of lysines. Another type of acetylation 
corresponds to the N-terminal (Nt) modification, which occurs at the N-termini of 
the nascent polypeptide chains and proteins (Drazic et al. 2016). Lysine acetylation 
is considered as a reversible PTM, and is catalyzed by lysine acetyltransferases 
(KATs) and regulated by lysine deacetyltransferases (KDACs). Whereas Nt-
acetylation is irreversible and catalyzed by Nt-acetyltransferases (NATs).  
It has been widely reported that lysine acetylation plays an important role in 
chromatin structure regulation and its transcriptional activity (Xu et al. 2014). The 
effect of acetylation on chromatin structure modulation may be due to an 
electrostatic mechanism, since the addition of an acetyl group neutralizes the 
positive lysine charge (Martin & Zhang 2005). Besides the effects of writers and 
erasers modulating cellular functions, modular domains, such as the bromodomain 
reader, a part of certain transcription factors and KATs, can bind to acetylated 
lysine and build large transcriptional and chromatin-remodeling complexes (Seo & 
Lee 2004; Filippakopoulos & Knapp 2012). 
 
Crosstalk between PTMs. Coordination between PTMs is essential for the 
regulation of different cellular pathways (Beltrao et al. 2013). PTM crosstalk can 
create a “code” on the protein surface that is recognized by specific domains 
leading to the activation or inhibition of downstream events (Lothrop et al. 2013). 
A certain PTM code delivers or retains the signal only if the surrounding input is 
present at the same time and place (Yang & Seto 2008; Venne et al. 2014; Yang & 
Qian 2017). PTM crosstalk has been classified into positive and negative events. In 
the positive form, the initial PTM actively triggers either the second PTM or serves 
as an interaction site for other proteins (Hunter 2007; Venne et al. 2014). In the 
negative form, there is direct competition between two PTMs for the same AA or 
an indirect effect when a specific PTM blocks the recognition of the second PTM, 
thus avoiding its addition or removal (Hunter 2007; Beltrao et al. 2013). The 
importance of the interplay between different PTMs relies on the efficient 
coordination between the PTMs, which allow signal translation into functional 
cellular processes. The most common enzymatic PTMs are summarized in Table 1. 
 
17 
Table 1.  Most common enzymatic PTMs in eukaryotes and their characteristics and 
functions. 
References provided in the text except where noted. *A single sugar: 203 or a chain: >800. 
εx cannot be P  (Moremen et al. 2012). αIt varies according to the enzyme, with P as 
important AA residue (Moremen et al. 2012). ± (Clarke 2013) Ψ, a hydrophobic residue. µx, 
any AA (Liddy et al. 2013). ƟCAAX: C, Cys; A, an aliphatic AA; x, any AA (Cho & Park 
2016). βGlycine in the N-terminal MGXXXS/T: M, Met; G, Gly; S, Ser; T, Thr; x, any AA (Cho 
& Park 2016). N.D, not determined (Jensen 2006; Kim et al. 2016). 
2.1.1 The role of protein PTMs 
In this section, phosphorylation cascades and crosstalk between distinct PTMs are 
presented to recognize how their interplay affects such functions as protein activity, 
cellular location, and protein interaction. As an example, the downstream signaling 
of the epidermal growth factor receptor (EGFR) kinase is briefly described from its 
initiation till its termination (Figure 2). 














N-Glycosylation >800 N NxS/Tε Protein folding, stability, 
O-Glycosylation 203, 
>800* 
S/T/Y α cellular interaction 
Acetylation 42 K  GK, KP Protein stability, PPIs 
Methylation 14 K/R/H± MK, RGG Transcription, protein-
nucleic acid interactions 
Ubiquitylation >1000 K varies Protein degradation 
SUMOylation 12,000 K ΨKxD/Eµ Subcellular transport 
Neddylation 9072 K varies Protein stability 
Myristoylation 210 G MGxxxS/Tβ Protein localization,  
Farnesylation 204 C CAAxƟ PPIs, protein-
membrane 
Palmitoylation 238 C varies interactions 
Sulfation 80 Y N.D Signalling, protein 
localization, PPIs 
Citrullination <1 R GxRGΨ Protein folding 
Oxidation 16 C/M C/S/TxxC Protein oxidative 
regulation 
Nitration 45 Y N.D Oxidative damage 
Hydroxylation 16 K/P N.D Structural stability 
(collagens) 
Crotonylation 68 K N.D Protein structure 





Figure 2. A simplified representation of the downstream signaling of the epidermal 
growth factor receptor (EGFR) kinase. After EGF binding to EGFR kinase, several 
phosphorylation events occur to mediate activation of several other protein kinases 
including AKT and MAPK. This activation drives cellular processes such as 
survival, protein synthesis, and proliferation. 
 
Several signaling pathways between the membrane and nucleus are activated by 
external stimuli upon the receptor tyrosine kinases (RTKs). This signal 
transmission can be attributed to the RTKs activity and the scaffolding and docking 
function of the receptors (Li & Hristova 2006). EGFR kinase is a receptor activated 
by epidermal growth factor (EGF) ligand binding, which results in 
autophosphorylation of tyrosine residues on the cytoplasmic receptor portion of 
EGFR (Wells 1999; Seo & Lee 2004; Kolch & Pitt 2010). Modification of the 
catalytic domain activates and potentiates the receptor functionality, while the 
modified non-catalytic domain builds docking sites for downstream targets, which 
bind to specific phosphotyrosine residues on the receptor, e.g. SH2 (Ge et al. 2002; 
Ferguson 2004; Seo & Lee 2004). For instance, active EGFR can recruit SH2-
containing proteins such as the growth factor receptor-bound protein 2 (Grb2) 
adaptor. This in turn recruits the guanidine nucleotide exchange factor (GEF) SOS, 
which stimulates a series of events that lead to the initiation of the downstream 
signaling pathway of mitogen-activated protein kinase (MAPK) for cell cycle 
progression and proliferation (Figure 2) (Deribe et al. 2010). Besides protein 
recruitment, active EGFR can also attract enzymes, such as the 
phosphatidylinositol 3-kinase (PI3K). This recruitment activates PI3K, which 
phosphorylates membrane phospholipids such as phosphatidylinositol 4,5-
bisphosphate (PIP2) becoming later in phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3). This phosphorylation generates docking sites on PIP3 for the enzymes 
phosphoinositide-dependent kinase-1 (PDK1) and protein kinase B (PKB), also 
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known as AKT (Figure 2) (Deribe et al. 2010; Rodon et al. 2013; Dienstmann et 
al. 2014). The result of this series of phosphorylation-mediated activation is the 
regulation of several cellular processes, including cell survival, metabolism, and 
protein synthesis (Rodon et al. 2013). 
Active EGFR and in general other RTKs are regulated by the correct amount of 
signal they have to deliver upon a stimulus. Inhibition of the EGFR catalytic 
activity is regulated by serine and threonine phosphorylation of its juxtamembrane 
domain exerted by the protein kinase C (PKC) (Chen et al. 1996). Moreover, signal 
attenuation is controlled by protein tyrosine phosphatases (PTPs), which 
dephosphorylate activated RTKs and downstream effectors (Tonks 2003). The 
main regulator of EGFR is rapid endocytosis and degradation of the EGF-EGFR 
complex. This involves EGFR ubiquitylation, which triggers the receptor 
internalization to early endosomes and future degradation (Deribe et al. 2010; 
Savio et al. 2016). Additionally, α-tubulin acetylation can control the velocity of 
the early endosomes motility, while deacetylation of the Lys40 of α-tubulin slows 
the EGFR degradation (Deribe et al. 2010). The interplay between distinct PTMs 
along a protein lifespan is determinant in the regulation of different cellular 
processes and is the foundation of the biological mechanisms underlying different 
diseases. 
2.1.2 PTMs impact in health and disease 
As Steffen et al. explained carefully in their review (Steffen et al. 2016), despite 
that the protein lifespan is strictly controlled by enzymes catalyzing almost all 
conversions with a defined activity, a perturbation is always possible. This 
perturbation can alter the quantity or quality of an enzyme which is in most of the 
cases linked to a pathological condition (Steffen et al. 2016). In the next section, 
perturbations in different stages of the protein lifespan and its association with 
some diseases are briefly reviewed. 
 
Protein synthesis, 10–50% of protein synthesis are estimated to result in defective 
ribosomal products due to incorrect coding or transfer, or both, within the 
ribosomal complex (Steffen et al. 2016). The quality of protein synthesis is 
controlled by different cellular systems located in the cytosol, endoplasmic 
reticulum (ER), mitochondria and nucleus. These systems are comprised of 
chaperones, which mediate the folding of the newly synthesized and refolding of 
the damaged proteins, and enzymes of the ubiquitin system, which identify and 
ubiquitylate misfolded proteins and prepare them for degradation (Steffen et al. 
2016). Accumulation of misfolded proteins causes cytotoxic effects in the cell, 
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which has been linked to the starting point of neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s (Thommen et al. 2017). 
 
Proteolytic processing of a protein is considered as an irreversible PTM which 
involves the cleavage of peptide bonds in a protein by enzymes called proteases. 
This can occurs several times during a protein lifespan and affects the activity of 
the protein target. For instance, during the maturation process of the 
transmembrane protein β-amyloid precursor protein (APP), a protein expressed at 
high concentration in neurons, three proteases enable protein maturation by 
converting the APP to the amyloid β-peptide (Aβ) (Haass et al. 2012). An error in 
this dynamic proteolytic event can cause precipitation of Aβ leading to diseases 
such as Alzheimer’s, which in this particular case is considered the major cause of 
the disease (Haass et al. 2012). To date, there is a lack of efficacy of the existing 
Aβ-targeted therapies for Alzheimer disease, so interest has been switched to Tau 
protein as a potential alternative target (Li & Götz 2017). 
 
Addition or removal of PTMs. As phosphorylation is the primary response of most 
of the cellular pathways, its dysregulation is observable in most human diseases. 
As an example, more than 150 kinases have been targeted for cancer anti-cancer 
drug development (Fleuren et al. 2016; Oliveira et al. 2018). For instance, mutation 
of upstream receptors such as EGFR, and downstream mediators such as 
phosphatase and tensin homolog (PTEN) have been reported especially in lung 
cancer (Rodon et al. 2013). Targeting drugs for specific kinases has been 
challenging since in most pathways there is usually a feedback loop that recovers 
the inhibited function upon drug exposure. Dual inhibitors can block alternative 
responses by targeting a pathway at two levels providing an advantage over 
specific inhibitors. Lately, effort has been focused on targeting not only enzymes 
from the same family, but also from different ones. For example, the CUDC-101 
inhibitor, a developing drug for solid tumors, which blocks histone deacetylase 
(HDAC), EGFR, and human epidermal growth factor receptor 2 (HER2) enzymes 
(Falkenberg & Johnstone 2014). The development of dual inhibitors has been 
challenging due to the complex cellular networks that each protein represents. 
However, such cases as the CUDC-101 inhibitor have been able to reach the 
clinical phase, giving promising results in the treatment of patients with squamous 
cell carcinoma, when used in combination with chemoradiation (Falkenberg & 
Johnstone 2014; Galloway et al. 2015).  
 
The formation of protein complexes is mediated by a variety of PTMs that 
modulate the binding affinities by altering electrostatic or structural properties of 
the protein interaction sites (Seet et al. 2006). It has been reported that more than 
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60% of PTM sites participate in PPIs,  modulating interaction and hence function 
(Duan & Walther 2015). Drug molecules targeting pathological PPIs are at the 
beginning of development. Despite the challenge of using small molecules for 
blocking the wide areas often associated with PPIs, the JQ1 inhibitor has been 
reported to disrupt the interaction between the bromodomain and acetylated lysine 
(Verdin & Ott 2015). JQ1 inhibitor has been initially tested in squamous cell 
carcinoma and has also been found to function as an immunosuppressant, 
suggesting other possibilities beyond cancer for this drug class (Verdin & Ott 2015; 
Zaware & Zhou 2017). 
 
Protein degradation plays an essential role in the regulation of protein abundance, 
and as indicated earlier is a control system for misfolded proteins. Ubiquitylation is 
a key PTM signal that delivers receptors from the cell surface to the lysosomes for 
degradation and is regulated by deubiquitylases, which catalyze the removal of 
K48-linked chains inhibiting degradation (Yau & Rape 2016). This process has 
been vastly studied for EGFR, in mammalian cells (Savio et al. 2016; Harrigan et 
al. 2018). The ubiquitin carboxyl-terminal hydrolase 8 (USP8) enzyme 
deubiquitylates EGFR on early endosomes and avoids its degradation (D’Arcy et 
al. 2015). In tumors such as glioblastoma, lung and breast cancer, EGFR is 
amplified or mutated at the tyrosine domain affecting the signal propagation and 
hence resulting in tumor cell proliferation (Harrigan et al. 2018). Inhibitors against 
USP8 have been reported, e.g., HBX90659 and its derivatives which have been 
shown to be efficacious in mouse models of lung cancer (Harrigan et al. 2018). 
 
One of the challenges in drug discovery and development is to identify the correct 
proteins that participate in a particular disease. In this regard, understanding protein 
roles, cellular networks of proteins or pathways in a cellular context can help to 
identify the best target in a disease state. Furthermore, with the development of 
improved technologies for proteomics, the identification of pathological proteins 
would be eased and could bring in the future new disease markers which can aid on 
the drug discovery and development process.  
2.2 The drug discovery and development process 
The drug discovery process (Figure 3) is a long journey which usually initiates 
with a scientific basis coming from academia. When developing a drug, sufficient 
research data is gathered to mainly prove that the modulation of a target (a protein) 
results in a therapeutic effect over a specific disease. Proper identification and 
validation of the targets and further hit-to-lead processes before the clinical 
development stage are needed. In this section, the generalities of early drug 
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discovery are discussed, covering the steps of the drug development process before 
the clinical development phase. 
 
Figure 3: An overview of the drug discovery and development process. The first 
step is to identify the best target involved in a disease, which can take between 12 
to 24 months. After that, chemical libraries are screened to find a hit that is then 
refined to improve its safety and effectiveness. Subsequent preclinical and clinical 
stages, including studies conducted in humans, take about 120 months, and it can 
take about 24 months for the FDA approval of the new medicine. 
2.2.1 Target identification and validation 
The selected target should meet clinical considerations, and most importantly, be 
druggable, i.e., accessible to the drug molecule to-be-developed, either small 
molecule or large biologicals. The challenge is to identify which target is relevant 
in a disease and in which form (Hughes et al. 2011). Enzymes, which are the most 
commonly targeted proteins, are naturally very dynamic targets as a result of 
substrate bindings, intermediates and products during the activity. A single target 
can represent a variety of different possibilities for drug intervention. In this 
context, the understanding of the mechanisms of activity of the target, covering 
structural characterization, partner interactions, environment characterization 
where the catalytic process occurs, and its related protein family, can render 
relevant information for compound design (Barnash et al. 2017; Holdgate et al. 
2018). Presently, drugs with different activities have been designed to target many 
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of different drug target forms through different modes (Figure 4). After the target 
has been selected, validation is assessed with techniques involving in vitro assays 
and eventually using animal models (Hughes et al. 2011). 
 
Figure 4. The kinetics of drug-target interactions. A single enzyme (E) may 
represent different targets for drug intervention. Enzymes bind substrates (S), 
intermediates (X) and products (P) during the catalytic cycle. Some examples of 
inhibitors (I) which bind to these different enzyme forms, either covalently 
(unidirectional arrow) or non-covalently, are shown. Figure modified from 
(Holdgate et al. 2018). 
2.2.2 Hit-to-lead generation 
In this phase, compound screening assays are used to find the ‘hit’ molecule. A hit 
is defined as the compound that has the desired activity in a screen and whose 
activity is confirmed upon retesting (Bleicher et al. 2003; Hughes et al. 2011). The 
primary screening begins with the library design or selection considering the 
structural similarity of the native binders and the binding site of each target. After 
that, HTS assays and computer-based software are run to find compounds or 
biologics that bind to the identified target. Although the HTS assay should give 
minimal false positive and negative hits, counter screen assays are performed to 
identify interfering compounds that could otherwise appear as hits. These screens 
are performed by removing the key component of the assay, such as the target. 
Additionally, orthogonal assays like isothermal titration calorimetry (ITC), MS, 
thermal shift assays, among others are performed to support and confirm the 
preliminary hits. Along this process, compound clusters are generated and 
evaluated to identify a structure-activity relationship (SAR) between the clusters 
and the target (Barnash et al. 2017). Additionally, cellular studies are performed to 
determine the selectivity and mechanism of action (MOA) of the hit series 
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providing information about the pharmacological effect of the drug under 
development (Barnash et al. 2017). The refined hit series gives more potent and 
selective compounds with pharmacological or biological activity, but requires more 
optimization in order to fit the target better. These are the lead compounds. 
2.2.3 Lead optimization 
In this phase, the aim is to maintain desired lead compound properties while 
reducing the deficiencies in the structure. The structure is modified to, e.g., 
improve the permeability of the compound through cellular epitheliums (Hughes et 
al. 2011). After the final characterization of the refined compound (preclinical 
candidate), in vivo model studies are performed before the clinical phase. The 
preclinical candidate should be tested for genotoxicity, high-dose pharmacology, 
pharmacokinetic and pharmacodynamic studies, dose linearity, drug-induced 
metabolism, and chemical stability (Hughes et al. 2011). All this information forms 
the basis of a regulatory submission to allow the human administration to begin in 
a phase called clinical development. 
2.3 Considerations for HTS assay development 
Several methods have been utilized for HTS assay development, including enzyme 
activity measurements from purified proteins, a reconstituted complex, a cellular 
extract or a phenotype in intact cells (Inglese et al. 2007). Regardless of the 
selected method, assays designed for HTS aim to obtain significant biological 
responses from the compound activities in a rapid manner. In this section, 
considerations for HTS assay development and post-screening analysis are 
reviewed. 
2.3.1 The in vitro assay components 
The target. A deep understanding of the physiological environment of the target is 
needed to mimic its natural condition and to be able to control its activity, substrate 
specificity and the compound structure activity relationship. Comprehensive 
characterization between the different target forms is also required in order to 
decide between the use of a truncated or full-length native enzyme, or multimeric 
protein complexes (Holdgate et al. 2018). Domain architecture, PTM status, 
activation state and artificial modification, such as affinity tags, can affect the 
target properties. Furthermore, the use of only the catalytic domain rather than the 
full-length protein can sometimes overlook allosteric sites that could provide a 
druggable site for inhibitor discovery. For example, it has been reported that 
allosteric inhibitors against the AKT serine/threonine protein kinases (AKT1-3) 
 
25 
can modulate the ‘native’ kinases with higher affinity than inhibitors developed 
with a truncated enzyme (Lindsley et al. 2005). Conversely, a catalytic domain of a 
protein can replace the use of the full-length version as in the case of the human β-
amyloid precursor protein cleaving enzyme (BACE1) catalytic domain, which was 
reported to function independently of the other protein domains (Holdgate et al. 
2018). Binding partners of the drug target can also influence its catalytic activity, 
as in the case of the binders of the histone-lysine N-methyltransferase enhancer of 
zeste homolog 2 (EZH2). The methyltransferase EZH2 catalyzes histone H3 
methylation only in the presence of its binding partners forming a pentameric 
complex (Holdgate et al. 2018). In this context, a profound research has to be 
invested in knowing the drug target to ensure that the right form of enzyme is 
represented. The more the target diverges from its natural state the more likely it is 
to identify compounds that lack a physiologically relevant mechanism. 
 
The target substrate refers to the modifiable peptide or protein recognizable by the 
drug target. When designing a substrate peptide for a target, some targets require a 
consensus sequence in the substrate in order to bind, while others are sequence 
insensitive. It is important to note that in vitro sequence selectivity may not reflect 
in vivo physiological relevance. For instance, the best known deacetylation 
substrate for SIRT6 is H3K9, which possess an arginine at the -1 position, a residue 
that is not preferred in vitro, according to the work of Steegborn et al. (Rauh et al. 
2013). Based on this, considering additional residues beyond the immediate 
consensus sequence may perhaps play an important role in recognition by the 
target. Moreover, for some targets, a native protein substrate is necessary to 
identify inhibitors that target the desired activity as in the case of the histone-lysine 
N-methyltransferase NSD2. Full-length nucleosome (which is the basic unit of 
deoxyribonucleic acid (DNA) packaging in eukaryotes, consisting of a DNA and 
histone protein cores), was reported to be required as the NSD2 substrate for lysine 
methylation of the histone H3 to provide fidelity of the biological target in a panel 
of kinetic isotope effect studies (Holdgate et al. 2018). The use of peptides as 
substrates could facilitate easier in vitro assays, but if no relevant response is 
obtained for the studied target, protein substrates should be considered. 
 
Cofactors are defined as any non-protein substance required for an enzyme to be 
catalytically active. Cofactors mediate the catalytic reaction or influence the 
enzyme structure. A cofactor may remain unchanged along the enzymatic reaction 
or may undergo through distinct states during the reaction cycle. It may strongly 
bind to the enzyme, or it can be transient, dissociating in equilibrium. Cofactors 
may be inorganic metal ion, e.g., Mg2+ as in the case of kinases (Adams 2001), or 
Zn2+ for deacetyltransferases (Wang et al. 2007), or organic compounds, e.g. 
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FAD/FADH2 involved in hydride transfer (Acker & Auld 2014). The enzyme-
cofactor affinity may be overly high that enzyme is purified with the cofactor, e.g., 
a Zn2+ ion bound to the active site in the case of HDAC enzymes (Boskovic et al. 
2016) or sometimes additional cofactor is needed in the HTS assay in order to 
maximize enzyme activity (Acker & Auld 2014). The concentration of the cofactor 
in the assay is also important as it influences the ability to identify a competitive 
cofactor compound in the screening. 
2.3.2 The HTS assay parameters 
Any HTS assay must fulfill the following parameters: a) sufficient sensitivity to 
allow detection of low potency compounds, b) reproducibility to support the 
validity of the obtained data, c) accuracy with regards to the positive and negative 
controls, and d) cost-effectiveness (Inglese et al. 2007). In order to determine if the 
developed assay is suitable for HTS, performance has to be assessed as part of the 
validation process. A series of statistical parameters evaluate assay performance 
including among the most common the Z'-value, signal-to-background (S/B) ratio, 
and the coefficient of variation (Table 2) (Zhang et al. 1999). In addition to these 
parameters, the developed assay should be tolerant to DMSO, as the chemical 
libraries are typically stored in that solvent. Usually, cell-based assays are 
intolerant to concentrations higher than 1% DMSO, while biochemical assays can 
tolerate up to 10%  (Hughes et al. 2011). 
 
Table 2  The most important equations for determining assay performance. 
σ, standard deviation of the assay signal; µ, mean of the assay signal; max, maximum 
signal; min, minimum signal. 
 
 
Parameter Equation Comment 
Coefficient of 
variation 
%𝐶𝐶𝐶𝐶 =  𝜎𝜎𝜇𝜇 × 100 
This measures the precision 
relative to the mean value, and 
is calculated for the maximum 
and minimum signals. An 
acceptable limit is <15%. 




Usually calculated using 
control compounds, 
acceptable value >2-fold. 
Z' factor 𝑍𝑍′ = 1 − (3𝜎𝜎𝑚𝑚𝑚𝑚𝑚𝑚 + 3𝜎𝜎𝑚𝑚𝑚𝑚𝑚𝑚)|𝜇𝜇𝑚𝑚𝑚𝑚𝑚𝑚 − 𝜇𝜇𝑚𝑚𝑚𝑚𝑚𝑚|
 
Represents the signal window 
using a score where a value 





After the HTS assay development, screening and hit identification, it is necessary 
to quantify the inhibitory effect of the hit compounds to determine which ones 
should progress for further testing and development. The quantification is 
determined by measuring the concentration at which the compound obtains 50% of 
its maximal inhibitory effect (IC50). Dose-response measurements are performed in 
which the enzymatic inhibition degree is monitored at increasing concentrations of 
the compound. It should be noted that the IC50 may not be a reflection of inhibitor 
affinity, since the value may be significantly affected by experimental conditions 
(Inglese et al. 2007). Usually, in HTS screening, the compound is premixed with 
the enzyme for a specific period, such thatno time-dependent inhibition effect is 
detectable. In some cases, non-specific inhibition may occur due to impurities, 
aggregators, precipitators, or compounds that bind to unfolded proteins (Holdgate 
et al. 2018). In general, these compounds are called pan-assay interference 
compounds (PAINS) and can result in misleading IC50 values as the inhibitory 
activity due to other effects leads to denaturation, inactivation or removal of the 
active protein from its catalytic function (Holdgate et al. 2018).  
Computational approaches, enzyme kinetics-based methods, and biophysical 
methods can help to identify such compounds. In general, the mechanism of 
inhibition can be either reversible or irreversible. Reversible inhibitors usually lead 
to full inhibition rapidly since non-covalent interaction is needed. Among this type 
there are competitive inhibitors, which usually have structural similarity with the 
substrate that accesses to the active site of the enzyme, uncompetitive inhibitors, 
which bind only to the enzyme-substrate complex, mixed type inhibitors, which 
bind both the free enzyme and the enzyme-substrate complex, and non-competitive 
inhibitors, which affect the enzyme activity without affecting the substrate binding. 
In the latter type, we find the allosteric inhibitors or activators, which bind and lead 
a change in the target conformation that leads to an inactive or active form of the 
target. In the case of irreversible compounds, they include non-specific protein 
denaturing agents that mostly interact with functional groups of the enzyme. 
2.3.4 Compound interference in HTS assays 
Every assay is prone to compound interference, which can be lead to false positive 
or false negative results. Commercially available assays have been developed with 
methods to rule out screening artifacts, for example, as with the ALPHAScreen 
TruHits kit from ALPHAScreen technology. This kit lists the possible types of 
interferences and strategies for assessing them including spectrophotometric 
analysis, biotin mimetics assays, and so forth. Compounds can interfere in a non-
specific manner with one of the assay reagents or with the signal generated from 
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σ, standard deviation of the assay signal; µ, mean of the assay signal; max, maximum 
signal; min, minimum signal. 
 
 
Parameter Equation Comment 
Coefficient of 
variation 
%𝐶𝐶𝐶𝐶 =  𝜎𝜎𝜇𝜇 × 100 
This measures the precision 
relative to the mean value, and 
is calculated for the maximum 
and minimum signals. An 
acceptable limit is <15%. 




Usually calculated using 
control compounds, 
acceptable value >2-fold. 
Z' factor 𝑍𝑍′ = 1 − (3𝜎𝜎𝑚𝑚𝑚𝑚𝑚𝑚 + 3𝜎𝜎𝑚𝑚𝑚𝑚𝑚𝑚)|𝜇𝜇𝑚𝑚𝑚𝑚𝑚𝑚 − 𝜇𝜇𝑚𝑚𝑚𝑚𝑚𝑚|
 
Represents the signal window 
using a score where a value 





After the HTS assay development, screening and hit identification, it is necessary 
to quantify the inhibitory effect of the hit compounds to determine which ones 
should progress for further testing and development. The quantification is 
determined by measuring the concentration at which the compound obtains 50% of 
its maximal inhibitory effect (IC50). Dose-response measurements are performed in 
which the enzymatic inhibition degree is monitored at increasing concentrations of 
the compound. It should be noted that the IC50 may not be a reflection of inhibitor 
affinity, since the value may be significantly affected by experimental conditions 
(Inglese et al. 2007). Usually, in HTS screening, the compound is premixed with 
the enzyme for a specific period, such thatno time-dependent inhibition effect is 
detectable. In some cases, non-specific inhibition may occur due to impurities, 
aggregators, precipitators, or compounds that bind to unfolded proteins (Holdgate 
et al. 2018). In general, these compounds are called pan-assay interference 
compounds (PAINS) and can result in misleading IC50 values as the inhibitory 
activity due to other effects leads to denaturation, inactivation or removal of the 
active protein from its catalytic function (Holdgate et al. 2018).  
Computational approaches, enzyme kinetics-based methods, and biophysical 
methods can help to identify such compounds. In general, the mechanism of 
inhibition can be either reversible or irreversible. Reversible inhibitors usually lead 
to full inhibition rapidly since non-covalent interaction is needed. Among this type 
there are competitive inhibitors, which usually have structural similarity with the 
substrate that accesses to the active site of the enzyme, uncompetitive inhibitors, 
which bind only to the enzyme-substrate complex, mixed type inhibitors, which 
bind both the free enzyme and the enzyme-substrate complex, and non-competitive 
inhibitors, which affect the enzyme activity without affecting the substrate binding. 
In the latter type, we find the allosteric inhibitors or activators, which bind and lead 
a change in the target conformation that leads to an inactive or active form of the 
target. In the case of irreversible compounds, they include non-specific protein 
denaturing agents that mostly interact with functional groups of the enzyme. 
2.3.4 Compound interference in HTS assays 
Every assay is prone to compound interference, which can be lead to false positive 
or false negative results. Commercially available assays have been developed with 
methods to rule out screening artifacts, for example, as with the ALPHAScreen 
TruHits kit from ALPHAScreen technology. This kit lists the possible types of 
interferences and strategies for assessing them including spectrophotometric 
analysis, biotin mimetics assays, and so forth. Compounds can interfere in a non-
specific manner with one of the assay reagents or with the signal generated from 




the assay detection type. Fluorescence and absorbance interferences are related to 
signal increase or reduction. For example, heterocyclic compounds fluoresce in the 
blue-green range, and can thereby interfere with coumarin-based assays which also 
excite or emit in that range (Inglese et al. 2007). Approaches including separation 
steps can minimize interferences as compounds are removed before the detection 
step. Nonetheless, these approaches are difficult to miniaturize and require high 
concentrations of reagents especially when using liquid handling robots. These 
assays are sometimes used as part of a hit confirmation process. Additionally, the 
use of lanthanide reporters, red-shifted fluorophores, and additional measurements 
along the screening can allow background subtraction in homogeneous assays. 
These fluorophores have a long lifetime luminescence that can be measured after 
the background fluorescence has decayed (Comley 2003; Inglese et al. 2007).  
Compound aggregation may affect signal increment or reduction due to 
enzyme denaturation, ligand sequestration or light scattering. Aggregation usually 
occurs at concentrations >1 µM, and to solve this, detergents such as Triton X-100 
(0.01-0.1%) can be added to disrupt the micellar structures of aggregates (Thorne 
et al. 2010; Acker & Auld 2014). Reporter enzyme-based assays such as the well-
known luciferase systems can be affected if the tested compound inhibits the 
detection enzyme. For instance, it has been reported that resveratrol, an activator of 
sirtuin 1, can inhibit luciferase, which has been used as a reporter in several assays 
(Inglese et al. 2007). 
2.4 HTS assays technologies for enzyme activity monitoring 
In this section, the principle of the approaches, and the advantages and 
disadvantages of the different HTS technologies are presented. The methods are 
exemplified considering mainly phosphorylation as a PTM model. The section is 
divided into radiometric and luminometric assays, and examples of HTS methods 
that combine biochemical and biophysical approaches are also briefly described. A 
summary of the most common PTM enzymes and their advantages and limitations 
is shown in Table 3 at the end of this section. 
2.4.1 Radiometric assays 
Radiometric assays traditionally applied to enzyme activity measurements, mainly 
in kinase activity monitoring. This technology relies on the conversion of a 
radioactively-labeled substrate (referred to here as the cofactor required for the 
enzyme activity) to a radioactive secondary product (the processed cofactor). The 
assay measures the radioactivity from the released product or the residual substrate 
after conversion. The advantage of this method is its specificity and sensitivity. 
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Radioisotopes allow the specific labeling of a single substrate without perturbing 
the biology of the reaction being studied, and the amount of radioactivity per 
labeled substrate can be measured making the system quantifiable. Some major 
requirements are needed in order to obtain a functional assay, including a simple 
method for quantitative separation of substrate and product, and availability of a 
labeled substrate with known specific radioactivity. These requirements can 
sometimes become limitations if they are not fully achieved. Additionally, the 
limited shelf-life of the radioactive labels leads to increased radioactive substrate 
production and therefore, relatively large amounts of radioactive waste, which have 
limited the use of the technique. A variety of radioactively labeled substrates for 
enzyme assays have been reported, including 32P-ATP, 14C-acetyl CoA, PAP35S 
and [3H]-acetylated oligopeptides for kinase (Ko et al. 2011), acetyltransferase 
(Rekowski & Giannis 2010), sulfotransferase (Paul et al. 2012), and histone 
deacetylase (Heltweg et al. 2005) assays, respectively. In the following section, the 
principle of two radiometric assay formats for enzyme activity monitoring are 
briefly described. 
 
The scintillation proximity assay 
 
The scintillation proximity assay (SPA) is a homogeneous method that uses 
microscopic beads containing scintillant that can be stimulated to emit light (Cook 
1996). Stimulation occurs when the radiolabeled molecules bind to the SPA bead 
surfaces bringing them into close proximity. When the radioisotopes decay, there is 
a release of β-radiation (or Auger electrons for 125I) that stimulates the scintillant 
in the SPA bead producing light which can be further detected using a scintillation 
counter or with a charge-coupled device (CCD) camera detector for imaging 
detection systems (Figure 5A) (Cook 1996; Glickman et al. 2008). As the free 
radioactive substrates are not in enough close proximity to the SPA bead to 
stimulate it, no washing steps are required. To improve the performance of the 
approach, SPA beads with red-shifted light emission have been implemented in 
order to reduce compound interferences related to their emission and absorption 
properties (Ma et al. 2008; Yu et al. 2014). Additionally, different versions of 
microtiter plates coated with polystyrene-based scintillant have been adapted for a 
direct assay, eliminating the need to add a scintillation cocktail for detection. 
 
Filtration binding assay 
 
Since the assay includes washing steps (heterogeneous assay type) it has been 
questioned whether this system can be considered as an HTS assay or not. 
However, a few commercially available platforms have been developed for large 
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kinase panels in HTS formats, for example, the Reaction Biology Corporation’s 
HotSpotSM (Anastassiadis et al. 2011) and Millipore’s KinaseProfiler (Gao et al. 
2013). In a standard assay, the enzymatic reaction is first performed in one assay 
plate and then filtered through a filter plate using a vacuum manifold. The 
radioactive product attaches to a special filter, while the residual unreacted material 
is washed away. The filters are dried, and a scintillation cocktail is added for 
detection. A variety of different filter materials are available for this technology, 
e.g., negatively charged phosphocellulose (PH) filters, which can retain 
phosphorylated peptides containing basic AA residues. The main advantage of this 
approach is its free-of-interference feature, however, the requirement for washing 
steps are a major limitation when applying this method on a large scale. In 
comparison with SPA assays, there is a greater assay variability and more 
radioactive waste, suggesting that the filtration binding assay format is better suited 




Figure 5. Radiometric assays for kinase activity monitoring. (A) In a scintillation 
proximity assay (SPA), the radioactively phosphorylated peptide binds to the SPA 
beads. After radioactive decay, β-particles from the 33P interact with the scintillant 
embedded within the beads and light is emitted. (B) In a filtration binding assay, 
the radioactively phosphorylated substrate peptide is retained in the 
phosphocellulose (PH) filter, and the residual reagents are washed away using 
vacuum filtration. A scintillation cocktail is used to react the radioactive molecules 






2.4.2 Luminometric assays 
Most of the currently available HTS assays are based on fluorescence and 
luminescence systems, since these are simple, relatively cost-effective, easy to 
automate, and are performed in a homogeneous format. This technology overcomes 
some of the problems related to the use of radioactivity, as it employs 
nonradioactive labels and only requires low sample volumes. A broad variety of 
traditional fluorophores, which have relatively short fluorescence half-lives (< 
µsec) are available. These include organic dyes, e.g., fluorescein, rhodamine, 
coumarin, Texas red and cyanine5, and biological fluorophores, such as green 
fluorescence protein (GFP), among others (Lavis & Raines 2007; Choulier & 
Enander 2010; Chudakov et al. 2010). The benefit of organic dyes over biological 
fluorophores is their small size, which allows their conjugation to macromolecules 
such as antibodies, without interfering with the biological function of the labeled 
target. Alternatively, biological fluorophores have the advantage that they can 
either be expressed alone or fused with proteins within cells, bacteria, or entire 
organisms (Li et al. 2008).  
Presently, longer half-life luminophores (µsec – msec), such as the lanthanide 
(Ln3+)-based probes, are widely used due to their favorable properties. Lanthanides 
provide a longer luminescence signal and an apparently wider Stokes shift when 
compared to the traditional fluorophores, which have mostly overlapping excitation 
and emission spectra (Hemmilä & Laitala 2005; Allen & Imperiali 2010; 
Charbonniere 2011). These properties provide a substantial reduction in 
background fluorescence from autofluorescence and help circumvent problems 
related to light scattering and self-quenching (Hagan & Zuchner 2011).  
Time-resolved luminescence (often referred as fluorescence - TRF) is a 
technology that was developed based on the use of Ln3+-based probes (Figure 6) 
(Hemmilä et al. 1984a). With this system, plate readers are set-up to include a 
delay time between the excitation and the reading time of the lanthanide emission 
signal, thus enabling autofluorescence subtraction. The difference with 
fluorescence intensity (FI) technology is the timing of the excitation and emission 
measurement processes being in the FI in a simultaneous manner which leads to a 
high background outcome (Hemmilä & Laitala 2005). Among the lanthanide 
series, europium and terbium probes have been widely applied in different assay 
formats (Hemmilä et al. 1997; Hewitt & Butler 2018). 
A variety of luminometric methods are available based on single and dual-
labels, antibodies, reporter enzymes, secondary products, the use of traditional 
fluorophores or TRF technology, and so forth. In the following section, a 
description of some of the techniques and their impact on HTS is presented. 
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Figure 6. The time-resolved luminescence (TRF) technology. After excitation by a 
pulse of light, the fluorescence decay of a lanthanide is emitted in µsec – msec, 
which allows subtraction of background fluorescence interferences that often occur 
on a time sub µsec time scale. 
 
Dissociation-enhanced lanthanide fluorescence immunoassays 
 
The dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) is a 
TRF-based method that involves substrate peptide binding and separation steps 
prior to detection (Figure 7) (Hemmilä et al. 1984a). In this heterogeneous kinase 
assay, a biotinylated substrate peptide is attached to a streptavidin-coated plate 
before the enzymatic reaction. For detection, the plate is washed several times 
before the addition of the non-fluorescent europium-labeled antibody that binds to 
phosphorylated peptides. More washing steps are then performed to remove the 
unbound labeled reagent. In the next step, an enhancement solution is added to 
dissociate the non-fluorescent europium ions into solution to form a highly 
fluorescent chelate with the components from the enhancement solution, and final 
measurement of the signals is performed (Takalo et al. 1994).  
This assay can decrease the interferences from compound fluorescence or 
fluorophore labeling since washing steps are included. The main disadvantage is 
that since it is a multistep process, which includes multiple washing cycles, it may 





Figure 7. The principle of the dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA). After the enzymatic reaction and washing steps, the non-
fluorescent europium (Eu)-labeled antibody is added to recognize the modified 
peptide. After the washing steps, the enhancement solution is added to dissociate 
the non-fluorescent europium ions and to form a highly fluorescent chelate that are 
detected after excitation. 
 
Fluorescence intensity assays 
 
The FI assay is based on the use of traditional fluorophores, and has been widely 
applied among assays that use protease-based detection reactions (Salisbury et al. 
2002). Transferase activity monitoring, such as kinase assays, have been developed 
using enzyme cascades for detection (Ma et al. 2008; Janzen 2014). For instance, 
in the commercially available method called ADP HunterTM, kinase activity is 
detected by means of the production of ADP, using reactions in cascades involving 
pyruvate kinase, pyruvate oxidase, and horseradish peroxidase. After enzyme 
activity, the pyruvate kinase detection enzyme converts ADP to ATP and 
phosphoenolpyruvate to pyruvate. Later the pyruvate oxidase converts pyruvate to 
hydrogen peroxide (H2O2), which is detected by using the fluorescent Amplex Red 
(10-acetyl-3,7-dihydroxyphenoxazine) and horseradish peroxidase, resulting in the 
production of highly fluorescent resorufin (Charter et al. 2006; Helenius et al. 
2012). In a different approach, the Promega’s ProFluor® method uses a rhodamine-
110 fluorophore which is conjugated to the substrate peptide. The rhodamine-110-
peptide is in a non-fluorescent form, and after the phosphorylation reaction, a 
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protease solution is added to stop the reaction and to digest the non-phosphorylated 
peptide. The digestion releases the fluorescent rhodamine-110 from the non-
phosphorylated peptide while the phosphorylated peptide is resistant to digestion 
and remains non-fluorescent. In this sense, the fluorescent intensity measured 
correlates to the kinase activity in the presence of the active protease (Ma et al. 
2008). The main disadvantages of this approach are related to autofluorescence 
interferences and the multistep nature of the detection process, which includes 
several reporter enzymes that could be inhibited by the tested compound. Also, it 
can  be challenging to develop peptides that are suitable for the studied target and 
the detection enzymes (Ma et al. 2008; Simeonov et al. 2008). 
 
Fluorescence polarization assays 
 
Fluorescence polarization (FP) is a single-label approach that depends on 
differences in the rotational properties of small vs. large molecules (Li et al. 2008). 
Fluorescent molecules are excited by a plane of polarized light and the emitted 
light is in the same polarization plane when the molecules do not substantially 
move or rotate during the excited state. Conversely, if the molecules rotate within 
the excited state lifetime, the polarized light is emitted in a different plane from the 
excitation polarization plane. In this sense, small molecules rotate rapidly thus 
becoming depolarized (low FP); and large molecules (or the association between 
small and large molecules) rotate insignificantly, and the emitting polarized light is 
in the same plane of the excitation polarization plane (high FP) (Checovich et al. 
1995; Nasir & Jolley 1999). The polarization change is detected by monitoring the 
amount of fluorescence in the parallel vs. perpendicular plane after excitation in the 
parallel plane. This single-label approach encompasses direct and competitive 
assay formats, which have been developed for a variety of enzyme targets (Zhang 
et al. 2007; Mazitschek et al. 2008; Brandt et al. 2013; Lewallen et al. 2014).  
In a direct measurement, the substrate peptide is fluorescently labeled, and after 
enzymatic activity, the modified peptide is recognized by a specific antibody 
leading to an increased polarization signal due to the decreased complex mobility 
(Kristjánsdóttir & Rudolph 2003). For example, in the competitive PolarScreen 
kinase assay, after the enzymatic reaction, the antibody and tracer are added to the 
reaction to initiate the competition for the antibody binding. The antibody 
recognizes the molecule in high concentration, either the fluorescently labeled 
tracer, which is a synthetically phosphorylated peptide (high FP value), or the 
phosphorylated substrate peptide produced by the kinase (lower FP value) (Figure 
8A) (Seethala & Menzel 1997; Kristjánsdóttir & Rudolph 2003; Li et al. 2008).  
In the case of the Transcreener kinase assay, the kinase activity is detected by 
measuring the ADP production. Antibodies bind either to the fluorescently labeled 
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ADP tracer (high FP value) or the ADP produced by the kinase activity (lower FP 
value) (Figure 8B) (Kumar & Lowery 2017). The Transcreener assay has been 
developed to detect a more extensive enzyme set, including non-nucleotide-
dependent enzymes such as methyltransferases. The detection is performed by 
using a secondary enzyme cascade, which produces AMP that is detectable with an 
antibody and using fluorescently labeled AMP as a tracer (Kumar et al. 2015).  
The advantage of the assays relies on the use of far-red tracers, which reduce 
interference from fluorescent compounds and light scattering due to their excitation 
and emission maxima above 600 nm (red wavelengths) (Vedvik et al. 2004). 
However, the use of enzyme cascades, and specifically the need of antibodies is 
typically the limiting factor. Anti-phosphotyrosine specific antibodies are relatively 
insensitive to the surrounding AA context. However, certain antibodies require a 
specific consensus sequence to bind to the modified target. For example, 
phosphoserine or phosphothreonine antibodies are highly dependent on the AA 
sequence surrounding the binding site, thus limiting the diversity of phosphorylated 
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ADP tracer (high FP value) or the ADP produced by the kinase activity (lower FP 
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phosphogroups can be free or linked to serine, threonine or tyrosine residues, or 
other molecules, which provides an advantage for measuring kinase, phosphatase 
or phosphodiesterase activity (Figure 9). Despite being an antibody-free system, 
the need for ATP concentration optimization and a specifically designed substrate 
peptide have limited the applicability of the IMAP method. Additionally, the 
number of carboxylic acid groups in the substrate peptide interfere with the 
detection component binding. Thus, long binding incubation is needed if more than 
five acid groups are present in the peptide sequence. Like IMAP, other FP assays 
have been developed using cationic polyamino acids (Coffin et al. 2000), or a 
mixture of ions and proteins that interact with the phosphorylated product (Scott & 
Carpenter 2003; Chopra et al. 2008). However, the nature of these approaches has 
limited their applicability to other enzyme types. 
 
 
Figure 9. The principle of the IMAP fluorescence polarization (FP) assay. The 
IMAP detection approach is based on the high-affinity binding between the 
phosphate group and the metal ion immobilized on the nanoparticles. After 
phosphorylation, detection component interacts with phosphate groups on the 
phosphorylated peptides. This interaction causes a change in the complex motion 
avoiding significant rotation and leading to high FP. Conversely, the non-
phosphorylated peptide can freely move, and low FP is monitored. 
 
Förster resonance energy transfer assays 
 
Förster resonance energy transfer (FRET) is a dual-label technique that relies on 
the energy transfer from an excited donor to an acceptor fluorophore (Li et al. 
2008). Some elemental requirements are needed, such as spectral overlap between 
donor emission and acceptor excitation, the distance between the donor and 
acceptor should be between 1 – 10 nm, and the labels should be favorably 
orientated. In a FRET assay, the FRET signal is monitored by measuring changes 
in the sensitized emission intensity of the acceptor (Berney & Danuser 2003; Roda 
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et al. 2009). Moreover, signals can be monitored by measuring the intensity 
decrease of the donor fluorescence due to FRET. This measurement is usually 
employed to corroborate FRET events. TRF technology has been applied to FRET, 
thus leading to the TR-FRET method.  
This method has proven its functionality and suitability for different enzymes, 
including transferases and hydrolases, generally utilizing the energy transfer from a 
lanthanide donor to an organic dye acceptor (Moshinsky et al. 2003; Carlson et al. 
2009; Degorce et al. 2009; Horton & Vogel 2010; Gauthier et al. 2012; Zielinski et 
al. 2016). For instance, in the LANCE kinase assay, a Ln3+-labeled 
phosphotyrosine antibody is used to monitor phosphorylation of an acceptor-
labeled peptide. Close proximity between the donor and acceptor leads to energy 
transfer and a high time-resolved luminescence (TRL) signal (Figure 10A) 
(Hemmilä 1999; Karvinen et al. 2002; Degorce et al. 2009; Horton & Vogel 2010; 
Gauthier et al. 2012). 
The main limitation of the FRET method is the need for specific antibodies. 
Furthermore, due to the close-proximity factor, incorrect orientation of the labels 
and free fluorophores can mask energy transfer by quenching the signal assay 
optimization can be challenging. 
 
Figure 10. The principle of two homogeneous proximity- and energy transfer-
based assays. (A) The LANCE kinase assay is a Förster resonance energy transfer 
(FRET) method that uses a lanthanide (Eu)-labeled antibody (donor) to recognize 
the phosphorylated substrate peptide (acceptor) and transfer energy from the 
excited donor to the acceptor molecule yielding to a high luminescence signal.  (B) 
The AlphaScreen kinase assay relies on a chemical energy transfer between the 
donor and the acceptor beads. In the kinase assay, the phosphorylated peptide binds 
to the Lewis metal chelate (LMC3+) on the phosphosensor (PhS) acceptor and the 
streptavidin (SA) coated on the donor bead. After excitation, a singlet oxygen 
reacts with the acceptor bead leading to a high the luminescence signal. 
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Amplified luminescent proximity homogeneous assay 
 
The amplified luminescent proximity homogeneous assay (ALPHA) technology is 
a proximity-based method like FRET that uses donor and acceptor beads to 
mediate the chemical energy transfer (Figure 10B) (Glickman et al. 2002). There 
are two technologies that have been developed using this concept, the 
AlphaScreen, and the AlphaLISA assays. After the donor and acceptor beads are 
brought into close proximity, a laser excitation at 680 nm activates a 
photosensitizer in the donor bead, which converts ambient oxygen to a more 
excited singlet state. The singlet oxygen reacts with a thioxene derivative in the 
acceptor bead generating chemiluminescence at 370 nm, which activates 
luminophores contained in the same bead emitting light at 520-620 nm, in the case 
of AlphaScreen, or 615 nm, with AlphaLISA beads. Since the lifetime of the 
singlet oxygen is around 4 µs, it can diffuse approximately 200 nm, which gives 
freedom to measure larger molecules compared to FRET. Besides, the emission 
wavelength is lower than the excitation, which allows reducing the background 
interference significantly. 
However, this technology may be sensitive to other interferences such as heavy 
metals, which act as singlet oxygen quenchers. These ions in solution can react 
with the singlet oxygen forming insoluble oxides and avoiding the chemical energy 
transfer (Eglen et al. 2008; Bielefeld-Sevigny 2009). 
 
Chelation-enhanced fluorescence assays 
 
The chelation-enhanced fluorescence (CHEF) assay, called Omnia, is a single-label 
antibody-free method that relies on the use of sulfonamide-oxine (Sox) as an 
artificial AA and physiological concentrations of Mg2+ (Figure 11) (Shults & 
Imperiali 2003). In this approach, the chelation-sensitive fluorophore Sox has 
heteroatoms that can coordinate with biologically or artificially available metal 
ions, such as Ca2+ and Mg2+ (González-Vera 2012). The fluorophore possesses a 
different electronic structure when coordinated than in the absence of the metal ion, 
and this is reflected in a change of its fluorescence properties (Krueger & Imperiali 
2013). In this context, the chelating properties of the phosphate group have been 
harnessed for kinase sensing under this approach. In a kinase activity assay, the 
phosphate group located in the vicinity of the coordinating fluorophore promotes 
the metal ion binding, producing an increase in the fluorescence signal (Luković et 
al. 2008). The kinase assays are monitored with 360 nm excitation and 485 nm 
emission with an average Mg2+ concentration of 10 mM. The key point is that 
before phosphorylation, Mg2+ binding is weak (100 mM < KD < 300 mM), while 
after phosphorylation, the affinity is increased (4 mM < KD < 20 mM). A high 
 
39 
concentration of phosphorylated peptide exists in the bound and fluorescent state in 
the presence of 10 mM Mg2+.  
The challenge of the approach is to achieve an effective metal-binding after 
phosphorylation. For this, careful placement of the CHEF fluorophore is needed to 
achieve high-affinity and selective metal ion binding. Hence, the initial peptide 
sequence has to be modified several times (Shults et al. 2006). Other assays have 
been developed for kinase activity using different indicators such as Ca2+, and Zn2+. 
Although CHEF is an antibody-free system, the approach has been limited to 
kinase assays (González-Vera 2012). 
 
Figure 11. The principle of the chelation-enhanced fluorescence (CHEF) assay. 
The assay uses a substrate peptide which contains the artificial Sox amino acid for 
sensing. After phosphorylation, the Sox residue undergoes chelation-enhanced 
fluorescence upon Mg2+ binding. The Sox residue is pre-organized for Mg2+ 
binding by a β-turn sequence. The chemosensor can be appended to either the C-





The firefly luciferase has been used as a reporter enzyme in HTS kinase assays.  
This enzyme catalyzes the oxidation of luciferin into oxyluciferin using ATP, 
oxygen, and Mg2+. The oxyluciferin, which is in an excited state, subsequently 
emits a yellow-green light with a spectral maximum of 560 nm (Lundin 2000). The 
commercially ADP-GloTM assay measures kinase activity by monitoring the ADP 
production using a luciferase reporter (Figure 12) (Zegzouti et al. 2009). The 
phosphorylation detection is performed in two steps. First, a reagent is added to 
stop the kinase reaction and to deplete the remaining ATP, and secondly a reagent 
is added to simultaneously convert ADP to ATP and allow this newly synthesized 
ATP to be measured using a luciferase reaction (Larson et al. 2009; Zegzouti et al. 
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2009). Since the light emission is derived from a biochemical reaction, no 
excitation source is needed, allowing the use of a simple luminometer for signal 
recording. Chemiluminescent assays can be used for any combination of kinase and 
substrate, regardless of its nature such as peptide, protein, sugar, and lipid (Ma et 
al. 2008). 
Although luciferase inhibitors may hamper the detection, there is already deep 
knowledge including an extended list of identified inhibitors that could help to 
address interference problems (Auld et al. 2009). A disadvantage of the system 
includes its low sensitivity and long assay times. The assay is not particularly time 
effective as the detection depends on two chemical reactions which consume an 
averaged time of approximately 90 min. 
 
Figure 12. The principle of a chemiluminescent kinase assay. In the ADP-GloTM 
kinase assay, after phosphorylation, the detection is performed in two steps. First, 
the remaining ATP has to be depleted, and second, the ADP produced by the 
kinase reaction is converted to ATP and utilized by the luciferase enzyme to 
convert luciferin in oxyluciferin. The luciferase reaction generates a yellow-green 
light which can be measured by a conventional luminometer. 
2.4.3 Other HTS assays 
Other assay types have been developed using combined biochemical and 
biophysical approaches. The mobility shift assay is a method that harnesses the 
charge difference between the modified status and the non-modified status of a 
fluorescently-labeled substrate peptide after the enzymatic reaction (Ma et al. 
2008). When the peptides are separated by electrophoresis, different mobilities are 
observed due to the charge difference of the modified vs. non-modified peptides. 
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Caliper Life Sciences developed a microfluidic chip-based assay for kinases using 
this approach. The enzymatic reaction occurs in the chip and is subsequently 
detected by electrophoretic separation, this is called an on-chip assay. The 
detection is performed using a microfluidic capillary electrophoresis instrument 
that measures the change in the relative fluorescence intensities of the substrate and 
product peaks (representing enzyme activity) (Elkins et al. 2016). Another version 
of the method is available, off-chip assay, where the enzymatic reaction occurs in a 
conventional microtiter plate and is further sipped into a microfluidic chip for 
separation and detection (Ma et al. 2008). The off-chip assay allows the 
measurement of temporal enzyme kinetics as the reaction mixture can be sipped at 
the different time points. Contrarily, the on-chip type needs a high conversion rate 
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 2.5 Concluding remarks 
Cell signaling networks are orchestrated by a variety of different proteins, each one 
interacting with several other proteins in various pathways and affecting the overall 
cellular function. The presence of protein isoforms with diversified roles in distinct 
cellular contexts, and of feedback loop mechanisms, which maintain a cellular 
event despite, for instance, the inhibition of a specific protein reveals the 
complexity of these cellular systems. It is clear that a profound understanding of 
this network helps in finding the most appropriate drug target for a disease, and the 
best drug design and screening approaches.  
Nowadays, the available HTS technologies offer the freedom to the end-user to 
select methods that suit best to their drug discovery goals. In general, an ideal HTS 
assay should be robust, sensitive, easy to optimize, cost-effective, and should be 
able to provide a significant measurable biological response. A variety of different 
HTS technologies for PTM enzyme assays rely on the detection of the modified or 
the secondary product produced after enzyme activity. In the case of 
phosphorylation, radiometric and some luminescence approaches measure enzyme 
activity by detecting the phosphorylated product. Other HTS assays detect the 
secondary product, in this case, ADP. As ADP is a universal kinase secondary 
product, the ADP detection approach can be applied to other different kinases. 
These PTM assays have been robustly developed for kinases and phosphatases and 
some other small-size PTMs. Moreover, in the case of the ADP detection method, 
indirect detection systems have been developed to expand the assay applicability to 
other PTMs. For instance, in methylation, the secondary product (SAH) is 
converted to an intermediate product and then to ADP, which can be then detected 
by the same approach. In general, the mentioned PTM detection approaches are 
based on antibodies, enzyme cascades, or chemical reactions, which may hamper 
their applicability to other PTM types. The current HTS technologies are yet not 
adaptable to some of the most important and complex targets involving 
SUMOylation, NEDDylation or glycosylation. The challenge to expand an HTS 
method to other PTM types depends perhaps on the enzymes involved. The 
selection of the detection method is target specific as the enzyme requirements and 
the enzymatic reaction itself vary among protein families. 
New complex targets for oncology, (Fleuren et al. 2016) including epigenetics 
(Filippakopoulos & Knapp 2014) or PPIs (Scott et al. 2016), neurodegenerative 
disorders (Li & Götz 2017), or rare diseases (Jen et al. 2016; Boycott & Ardigó 
2018), are continually emerging, suggesting there is a demand for new strategies 
and more versatile technologies capable of fulfilling the unmet drug development 
needs for novel targets.  
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The quenching resonance energy transfer (QRET) technique is a homogeneous, 
simple and single-label assay concept based on a luminescence difference between 
target molecule bound to a Ln3+-ligand and a free Ln3+-ligand (Kopra & Härmä 
2015). When the Ln3+-ligand is free in solution, the chelate is exposed to the 
soluble quencher molecule which attenuates the luminescence signal. Contrarily, 
when the Ln3+-ligand is in complex with the target molecule, the chelate is 
protected against quenching and a high luminescence signal is detected. The ligand 
can be a peptide, aptamer, nucleotide or any low molecular weight molecule 
incapable of protecting the Ln3+ luminescence from quenching (Kopra & Härmä 
2015). This technique has been extensively reported for screening assays for 
different targets, such as GPCRs proteins, estrogen receptor-ligand binding, and 
small GTPases (Rozwandowicz-Jansen et al. 2010; Huttunen et al. 2011; 
Martikkala et al. 2011; Kopra et al. 2014b, 2017). The advantage of the technique 
relies on its simplicity and sensitivity. The QRET is simple as it is designed in a 
single-label approach, there is no need for long incubations, and the detection 
component can be added in a single step. It is sensitive due to the use of the TRL 
detection, and due to all these attributes, it can be optimized in a cost-effective 
manner. The challenge relies on the need for small ligands for Ln3+ conjugation. 
The labeled molecule should preferably be a low molecular weight ligand to avoid 
self-protection of the Ln3+. Additionally, depending on the application, the use of a 
high concentration of total protein in the tested reaction can sometimes affect the 
system by quenching the overall luminescence signal, thus affecting the assay 
sensitivity. Sometimes a tested compound can act as a quencher by absorbing light 
at the emission wavelength of the Ln3+. However, the influence of such quencher 
compounds are associated with all HTS technologies that rely on a luminescence-
based detection. The implementation of the QRET technique approach presents a 
possibility to develop QRET-based assays for different PTM targets that may have 
found difficulties in the existing HTS technologies. 
If the drug discovery and development community are willing to embrace new 
approaches, there would be more opportunities to obtain the desired outcome, 
perhaps in the earliest stages of the drug discovery and development, thus possibly 
resulting in a better clinical translation and subsequent better treatments.
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component can be added in a single step. It is sensitive due to the use of the TRL 
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self-protection of the Ln3+. Additionally, depending on the application, the use of a 
high concentration of total protein in the tested reaction can sometimes affect the 
system by quenching the overall luminescence signal, thus affecting the assay 
sensitivity. Sometimes a tested compound can act as a quencher by absorbing light 
at the emission wavelength of the Ln3+. However, the influence of such quencher 
compounds are associated with all HTS technologies that rely on a luminescence-
based detection. The implementation of the QRET technique approach presents a 
possibility to develop QRET-based assays for different PTM targets that may have 
found difficulties in the existing HTS technologies. 
If the drug discovery and development community are willing to embrace new 
approaches, there would be more opportunities to obtain the desired outcome, 
perhaps in the earliest stages of the drug discovery and development, thus possibly 
resulting in a better clinical translation and subsequent better treatments.




3 AIMS OF THE STUDY 
The main objective of the work presented from this doctoral thesis was to develop 
a universal biochemical HTS method for protein PTMs monitoring using the 
QRET technique in an antibody-free system. Ultimately, this would provide a 
simple, sensitive and versatile detection method that allows measurement of a wide 
range of different PTM types. The applicability of the QRET technique for PTM 
enzymatic activity assays was first demonstrated in an antibody-based system for 
tyrosine phosphorylation monitoring. On the basis of this, the universal detection 
method was further developed using the QRET technique in an antibody-free 
system. Under this framework, a novel tool is presented, which is referred to as 
“the peptide-break technology.” 
 
More specifically, the aims of the original publications were: 
 
I  To demonstrate the suitability of the QRET technique for PTM enzymatic 
activity monitoring in a homogeneous single-label tyrosine EGFR activity 
assay. 
 
II  To develop a universal homogeneous single-label detection technology for 
PTM monitoring using the QRET technique and the leucine zipper concept. 
 
III  To simplify the universal PTM detection technology using a peptide dimer 
approach exclusively based on electrostatic interactions to enable freedom 
for substrate peptide design. 
 
IV  To study the applicability of the universal peptide-break technology in a 








4 MATERIALS AND METHODS 
 
A brief summary of the materials and methods used in this project are presented 
here. For more detailed information refer to the original publications (I-IV). 
4.1 Labels and quencher molecules 
All the assays were developed using the QRET technique as a detection system 
which consisted of a Eu3+-labeled molecule and a soluble quencher. 
4.1.1 Lanthanide chelate 
The nonadentate Eu3+-chelate-9d, {2,2′,2′′,2′′′-{[2-(4-
isothiocyanatophenyl)ethylimino]-bis(methylene)bis{4-{[4-
(agalactopyranoxy)phenyl]ethynyl}-pyridine-6,2-diyl}bis(methylenenitrilo)} 
tetrakis(acetato}europium(III) was purchased from BN Products&Services (Turku, 
Finland). The excitation and emission maximum of the Eu3+-chelates are 
approximately 340 nm and 615 nm, respectively. 
 
Eu3+-chelate conjugation to peptides (I-IV). In all the label conjugations, the 
isothiocyanate group of the Eu3+-chelate reacted with the primary amino group of 
the peptides. The lysine amino groups present in the sequence were synthetically 
protected with Fmoc groups. Subsequent Fmoc removal was performed after label 
conjugation and before purification using 30% of piperidine. All the HPLC 
purifications were performed using reversed-phase adsorption chromatography 
(Dionex 3000 LC system), and an Ascentis RP-amide C18 column. An eluent 
system containing 50 mM triethylammonium acetate buffer (TEAA) pH 7.0 and an 
acetonitrile linear gradient was used. The Eu3+-peptide concentration was 
determined based on the Eu3+-ion concentration by comparing observed 
luminescence signals to a commercial Eu3+-standard (Hemmilä et al. 1984b). In 
publication I, the Eu3+-chelate was conjugated to a substrate peptide for a single-
peptide EGFR assay (I), and to a detection peptide for a dual-peptide assay (II-IV). 




3 AIMS OF THE STUDY 
The main objective of the work presented from this doctoral thesis was to develop 
a universal biochemical HTS method for protein PTMs monitoring using the 
QRET technique in an antibody-free system. Ultimately, this would provide a 
simple, sensitive and versatile detection method that allows measurement of a wide 
range of different PTM types. The applicability of the QRET technique for PTM 
enzymatic activity assays was first demonstrated in an antibody-based system for 
tyrosine phosphorylation monitoring. On the basis of this, the universal detection 
method was further developed using the QRET technique in an antibody-free 
system. Under this framework, a novel tool is presented, which is referred to as 
“the peptide-break technology.” 
 
More specifically, the aims of the original publications were: 
 
I  To demonstrate the suitability of the QRET technique for PTM enzymatic 
activity monitoring in a homogeneous single-label tyrosine EGFR activity 
assay. 
 
II  To develop a universal homogeneous single-label detection technology for 
PTM monitoring using the QRET technique and the leucine zipper concept. 
 
III  To simplify the universal PTM detection technology using a peptide dimer 
approach exclusively based on electrostatic interactions to enable freedom 
for substrate peptide design. 
 
IV  To study the applicability of the universal peptide-break technology in a 








4 MATERIALS AND METHODS 
 
A brief summary of the materials and methods used in this project are presented 
here. For more detailed information refer to the original publications (I-IV). 
4.1 Labels and quencher molecules 
All the assays were developed using the QRET technique as a detection system 
which consisted of a Eu3+-labeled molecule and a soluble quencher. 
4.1.1 Lanthanide chelate 
The nonadentate Eu3+-chelate-9d, {2,2′,2′′,2′′′-{[2-(4-
isothiocyanatophenyl)ethylimino]-bis(methylene)bis{4-{[4-
(agalactopyranoxy)phenyl]ethynyl}-pyridine-6,2-diyl}bis(methylenenitrilo)} 
tetrakis(acetato}europium(III) was purchased from BN Products&Services (Turku, 
Finland). The excitation and emission maximum of the Eu3+-chelates are 
approximately 340 nm and 615 nm, respectively. 
 
Eu3+-chelate conjugation to peptides (I-IV). In all the label conjugations, the 
isothiocyanate group of the Eu3+-chelate reacted with the primary amino group of 
the peptides. The lysine amino groups present in the sequence were synthetically 
protected with Fmoc groups. Subsequent Fmoc removal was performed after label 
conjugation and before purification using 30% of piperidine. All the HPLC 
purifications were performed using reversed-phase adsorption chromatography 
(Dionex 3000 LC system), and an Ascentis RP-amide C18 column. An eluent 
system containing 50 mM triethylammonium acetate buffer (TEAA) pH 7.0 and an 
acetonitrile linear gradient was used. The Eu3+-peptide concentration was 
determined based on the Eu3+-ion concentration by comparing observed 
luminescence signals to a commercial Eu3+-standard (Hemmilä et al. 1984b). In 
publication I, the Eu3+-chelate was conjugated to a substrate peptide for a single-
peptide EGFR assay (I), and to a detection peptide for a dual-peptide assay (II-IV). 




4.1.2 Soluble quencher molecule 
Quenchers were chosen according to the absorption spectra. All the quenchers were 
stored in DMF (QRET Technologies). The Quench III was used in publication I, 
MT2 was utilized in II-III, and MT10 in IV. 
4.2 Instrumentation and instrument settings 
4.2.1 Plate reader for TRL-signal measurements 
The TRL-signal from the Eu3+-chelate was monitored with a Victor 1420 
multilabel counter (PerkinElmer) or a plate reader from Labrox Ltd. Measurements 
were performed at 615 nm, using 340 nm excitation wavelength with 400 µs (I) or 
600 µs delay time, and 400 µs decay time (I-IV). Black Optiplate 384F (I-III) or 
black Framestar 96-well microtiter (IV) plates were used for homogeneous assays, 
while an anti-mouse IgG 96-well plate for heterogeneous assays (I). 
4.2.2 Circular dichroism spectroscopy 
Circular dichroism (CD) measurements of the non-labeled peptides (II) were 
carried out at room temperature (RT) in a 1 mm cuvette using a Chirascan CD 
spectrometer from Applied Photophysics Ltd (Leatherhead, UK). The CD signal 
was monitored from 190 to 250 nm in 1 nm steps with an averaging time of 5 
seconds at each wavelength. 
4.2.3 Thermal shift assay 
The thermal shift assays were conducted using a PTC-100 thermal cycler for the 
heating process and a Victor multilabel counter for TRL-signal measurements. The 
signals were collected after a 3 min incubation at the chosen temperature. 
4.3 Assay buffer selection and peptide design 
All buffers were selected according to the enzyme requirements (Table 4). The 
substrate peptides were designed in-house by considering the enzyme’s consensus 
sequence and the assay’s detection approach (I-IV). The detection peptides 
followed the Fos/Jun leucine zipper (LZ) sequences (II, IV) and the peptide net 






Table 4.  Buffers used for the PTM enzyme assays. 
In publications II-IV, the detection component was added in AB2. 
   
Table 5.  Peptides used for PTM monitoring in this doctoral work. Modification sites 
of the substrate peptides are underlined. 
*Net charge at pH 7.5. **PEP4-6 represented the phosphorylated version of PEP1-3, respectively. ¤AA= amino acid 
Publication PTM Buffer 
I Phosphorylation 
AB1: 25 mM Tris, pH 7.45, 10 mM MgCl2, 0.5 mM EDTA, 
0.01% Triton X-100 
II, III, IV Phosphorylation, 
dephosphorylation 
AB2: 10 mM HEPES (pH 7.5), 0.1 mM EDTA, 0.01% 
Triton, 5 mM NaCl, and 1 mM MgCl2 
II, III, IV Deacetylation 
AB3: 10 mM HEPES (pH 8), 0.1 mM EDTA, 0.01% 
Triton, 25 mM NaCl, 2.7 mM KCl, and 1 mM MgCl2 
II, III Citrullination 









PTM modification site 
I PEP1** - Phosphorylation   Eu3+-EEEYEEEVEEEVEEE 
I PEP2** - Phosphorylation   Eu3+-EEYEEEEVEEEVEEE 
I PEP3** - Phosphorylation   Eu3+-EYEEEEEVEEEVEEE 
II Jun LZ Phosphorylation 36 - -Y- 
II p-Jun LZ Phosphorylated 36 - -pY- 
II Fos LZ Detection 36 - - 
II Tyro-LZ LZ Phosphorylation 35 - -Y- 
II TyroP-LZ LZ Dephosphorylation 35 - -pY- 
II, III Ser-LZ LZ Phosphorylation 35 - -RRxS- 
II, III LysAc-LZ LZ Acetylated 35 - -(Ac)KGA- 
II, III ArgLZ LZ Citrullination 35 - - SGRGK - 
II, III, IV Eu3+-LZ LZ Detection 35 - - 
III Eu3+-CPR1 Charge Detection 15 -12 - 
III Eu3+-CPR2 Charge Detection 27 -23 - 
III CP1 Charge Phosphorylation 19 +10 GGRRRVSRRVRRRVSRRGG 
III CP2 Charge Phosphorylation 21 +13 GGRRRVSRRVRRRVSRRVR
RR 
III CP3 Charge Phosphorylation 34 +23 GGRRRVRRRVSRRVRRRVR
RRVRRRVSRRVRRRK 
III CP4 Charge Citrullination 17 +10 - SGRGK - 
III CP5 Charge Citrullinated 17 +8 -SG(CIT)RGK- 




III, IV CP7 Charge Acetylation 17 +10 GRARKGARRARKGARRR 
IV CP8 Charge Methylation 19 +10 GRARTKQTRRARTKQTRRR  
IV CP9 Charge Methylated 19 +10 GRART(met-1)KQTRRART(met-
1)KQTRRR 
IV LZ-Y LZ Phosphorylation 35 - REELRKRRAELRRRYAQLRQ
RREQLRQRYANLRKE 
IV LZ-pY LZ Dephosphorylation 35 - REELRKRRAELRRRpYAQLR
QRREQLRQRpYANLRKE 
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4.4 Optimization of the homogeneous EGFR activity assay (I) 
A series of assays were performed to understand and demonstrate the functionality 
of the approaches and to select the optimal assay conditions. Later, assays were 
performed with the optimized conditions for validation purposes. 
 
Substrate peptide selection was first assessed in a homogeneous QRET binding 
assay using PEP4-6 (10 nM) and 4G10 antibody (187 ng/well). First, PEP4-6 and 
the antibody were incubated in 40 µl for 5 min. Next, 10 µl of Quench III (3.6 µM) 
was added, and the TRL-signal was measured during 60 min. Later, an EGFR 
enzymatic assay was performed using 10 nM PEP1-3, 50 μM ATP, 2 nM EGFR, 
and AG-1478 inhibitor (0 and 2 μM). All the enzymatic components were 
incubated in 10 μl for 30 min at RT. Next, the antibody and Quench III were 
added in 40 μl using the same concentrations and measurements as in the binding 
test. 
 
Antibody concentration selection. An antibody titration (0-374 ng/well) was 
performed with phosphorylated PEP4 (10 nM), EGFR (0 and 2 nM), ATP (0 and 
50 µM) and Quench III (3.6 µM) in a homogeneous binding assay. First, all 
reagents except the antibody were added in 40 µl, incubated 5 min and measured. 
Next, 10 µl antibody was added and measured as previously described. Also, an 
EGFR titration (0-50 nM) was performed with 40 ng/well of 4G10 antibody in a 
heterogeneous binding assay. First, 50 μl of antibody was added to the anti-mouse 
IgG plate, incubated for 60 min and washed (4x). Next, a 50 μl mixture of PEP4 
(10 nM) and varying EGFR concentrations was added, incubated 15 min, washed 
and measured. The assay used Kaivogen buffer and Kaivogen wash solution. 
 
EGFR concentration selection and assay validation. An EGFR titration (0.5, 1.0, 
2.0, and 5.0 nM) with PEP1 was performed in an enzymatic assay to find the 
suitable EGFR concentration. The optimized assay condition consisted of 2 nM 
EGFR, 10 nM PEP1, 50 μM ATP, 187 ng/well antibody and 3.6 μM Quench III. 
Next, the assay was validated with a panel of EGFR inhibitors (AG-1478, 
compound 56, erlotinib, PD174265, and staurosporine). Inhibitor titration (0 to 5 
µM) was performed with the optimized assay condition. 
4.5 Optimization of the peptide-break technology (II-IV) 
All the assays were performed in 50 µl per well unless otherwise stated. Standard 
protocols for binding and enzymatic assays were used along the optimizations. In 
the homogeneous QRET binding assay, peptides (substrate and detection peptides) 
were incubated for 5 min before TRL-signal measurement. Next, quencher was 
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added, and the TRL-signal was measured multiple times during 60 min. In the 
homogeneous PTM enzymatic assays (Table 6), the reaction was performed in 10 
µl, and the detection component (Eu3+-peptide and quencher) was added in 40 µl. 
First, the inhibitor or activator was added, followed by the enzyme, substrate 
peptide and cofactor and incubated at RT during 30-45 min. Next, the detection 
component was added and measured as in the binding assay. Citrullination assays 
were performed with 1 mM CaCl2 added together with the enzyme, and in HDAC3 
deacetylation assays, the inhibitor was pre-incubated with the enzyme for 10 min 
before the substrate peptide addition. 
 
Table 6.  Assay conditions for the PTM enzymatic assays (II-IV). 
 
*A low enzyme concentration was used to obtain an improved assay window for the activator. Concentrations are given 
considering the final volume of 50 µl per well. 
4.5.1 The peptide-break technology using the leucine zipper peptides (II) 
Helicity of the leucine zipper (LZ) peptides was studied using circular dichroism 
(CD) spectroscopy. The peptide dimers, Jun/p-Jun with Fos and Tyro-LZ/TyroP-
LZ with EuLZ, were measured at 30 µM using PBS (pH 7.4). Three replicates for 
each sample were prepared, and the final signal was the triplicate average corrected 
for the buffer signal. 
 
Affinity studies of the peptide dimers was studied in a homogeneous QRET binding 
assay. Titration (0.1 nM-15000 nM) of Jun/p-Jun with 2 nM Eu3+-Fos and Tyro-
LZ/TyroP-LZ with 0.5 nM Eu3+-LZ using MT2 quencher was performed in AB2 
buffer. 
 
Homogeneous PTM enzymatic assays in an end-point mode were performed to 
optimize the assay conditions and to validate the optimized assays. Inhibitor 











II Phosphorylation 0.5, EGFR 10 50, ATP 10 3, MT2 
II, III Phosphorylation 0.5, PKA 10 50, ATP 10 3, MT2 
II Dephosphorylation 3.0, PTP1B 10 - 10 3, MT2 




5 3, MT2 
II, III Deacetylation 0.5, HDAC3 10 - 10 3, MT2 
II, III Citrullination 1.0, PAD4 10 - 10 3, MT2 
III Phosphorylation 2.0, PIM1-3 10 50, ATP 10 3, MT2 
IV Dephosphorylation 1.5, PTP1B 10000 - 1 500, MT10  
IV Deacetylation 1.5, HDAC3 10000 - 1 500, MT10 
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II Phosphorylation 0.5, EGFR 10 50, ATP 10 3, MT2 
II, III Phosphorylation 0.5, PKA 10 50, ATP 10 3, MT2 
II Dephosphorylation 3.0, PTP1B 10 - 10 3, MT2 




5 3, MT2 
II, III Deacetylation 0.5, HDAC3 10 - 10 3, MT2 
II, III Citrullination 1.0, PAD4 10 - 10 3, MT2 
III Phosphorylation 2.0, PIM1-3 10 50, ATP 10 3, MT2 
IV Dephosphorylation 1.5, PTP1B 10000 - 1 500, MT10  
IV Deacetylation 1.5, HDAC3 10000 - 1 500, MT10 




titrations (0-100 µM) were performed against EGFR (AG-1478, compound 56, 
erlotinib, PD174265, and staurosporine), PKA (staurosporine, H-7, and H-89), 
PTP1B (Na3VO4, and TCS-401), HDAC3 (TSA), Sirt1 (EX527) and a Sirt1 
activator (SRT1720). For PAD4 assay, CaCl2 titration (0.5, 1.0, and 5.0 mM) was 
performed using GSK484 (5 µM) as a negative control. The assay conditions are 
shown in Table 6. Additionally, the peptide-break technology was demonstrated 
for kinetic measurements in PKA and EGFR assays using 20 μl final volume. In 
the PKA assay, 2 nM Ser-LZ peptide, 1 nM Eu3+-LZ, and 1.5 μM MT2 quencher 
were incubated for 5 min. Next, a mixture of 1 nM PKA and 50 μM ATP was 
added to start the enzymatic reaction and the direct TRL-signal measurement (“0-
time point”). The EGFR assay was performed using 8 nM Tyro-LZ, 1 nM EGFR, 
50 μM ATP, 3 nM Eu3+-LZ, and 1.5 μM MT2 in the same manner. 
 
Inhibitor screening assay using the PKIS library was performed to validate the 
approach. Before the screen, EGFR and PKA assay miniaturization was performed 
from 50 to 10 µl final volume. DMSO tolerance was studied with varying DMSO 
concentrations (0-10%) in the 10 μl miniaturized assay. The assay conditions were 
10 nM peptide, 50 μM ATP, and 0.5 nM PKA/1 nM EGFR. For detection, 10 
nM/5 nM Eu3+-LZ and 3 μM/2 μM MT2 quencher were used in PKA/EGFR 
assays. The screening assays used 356 compounds from the Published Kinase 
Inhibitor Set (PKIS) library in a single data point (1 μM) for each compound. 
Also, 96 points for 0 and 1 μM of staurosporine were used as controls and to 
measure the assay robustness (Z' factor) from the three assayed plates. 
4.5.2 The peptide-break technology using the charge-based peptides (III) 
Substrate peptide selection. First, a homogeneous QRET binding assay was 
performed to define the optimal charge and affinity for the charge-based (CP) 
peptides. In the assay, CP1-3 and Ser-LZ peptides (10 nM) were tested with Eu3+-
LZ detection peptide (10 nM) and MT2. Next, a homogeneous QRET enzymatic 
assay with PKA kinase, H-89 inhibitor (0 and 2 μM), and CP1-3 and Ser-LZ 
peptides was performed to obtain assay window between modified and non-
modified peptide. The assay conditions are shown in Table 6. Later, binding tests 
with CP-peptides for citrullination (CP4/CP5) and deacetylation (CP6/CP7) and the 
same detection component were performed to optimize the assays. 
 
Homogeneous PTM enzymatic assays. Inhibitor titrations (0-25 µM) were 
performed against PKA, PIM1-3, PAD4, and HDAC3 enzymes to validate the 
assays. H-89 and staurosporine inhibitors were used in the PKA assay, while 
staurosporine in the PIM1-3 assays, both assays with CP1 peptide. The PAD4 
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assays used CP4 and Arg-LZ peptides and GSK484 inhibitor. The HDAC3 assay 
used CP6 and LysAc-LZ peptides and TSA inhibitor. The assay conditions are 
shown in Table 6. 
 
Detection peptide selection was performed using binding and enzymatic assays. 
Different charged detection peptides, Eu3+-CPR1 and Eu3+-CPR2, and a LZ-
detection peptide Eu3+-LZ were studied with CP1-3. The assay conditions are 
shown in Table 6. 
4.5.3 The thermal dissociation assay using the peptide-break technology 
(IV) 
Homogeneous thermal dissociation assay was performed to measure the thermal 
detachment profile of the peptide dimers. LZ-peptides for dephosphorylation (LZ-
Y/LZ-pY), CP-peptides for deacetylation (CP6/CP7) and demethylation 
(CP8/CP9), and Eu3+-LZ detection peptide were used in the experiments. In the 
assay, substrate peptides (10 μM) and a mixture of Eu3+-LZ (1 nM) and MT10 
(0.5 mM) were added to a 96-well plate and incubated 5 min. Next, the plate was 
heated from 25 °C (RT) to 90 °C using a thermal cycler, and the TRL-signal was 
recorded every 5 °C with a 3 min incubation at the chosen temperature. Later, a 
thermal binding assay using different ratios of phosphorylated (LZ-pY) and non-
phosphorylated (LZ-Y) peptides and Eu3+-LZ (1 nM) was performed to understand 
the assay sensitivity. In the assay, LZ-Y peptides were added to the LZ-pY solution 
in varying percentage (0, 0.5, 1, 5, 7, and 100%) keeping a 10 μM final 
concentration of LZ-Y and LZ-pY in the well. 
 
PTM enzymatic monitoring using the thermal dissociation assay. Inhibitor 
titrations (0-1 µM) were performed against PTP1B and HDAC3 enzymes using 
Na3VO4 and TSA inhibitors, respectively. The enzymatic assay was performed as 
previously described. Assay conditions are shown in Table 6. Additionally, a 
thermal dissociation assay using single-flash heating was performed to increase the 
assay throughput. The optimal temperature was reached using a single flash 
heating, and the plate was kept 3 min at it before the measurement. The Z' factor 
was determined for PTP1B and HDAC3 assays using 18 positive and 18 negative 
controls (Na3VO4 and TSA at 5 µM). 
 




titrations (0-100 µM) were performed against EGFR (AG-1478, compound 56, 
erlotinib, PD174265, and staurosporine), PKA (staurosporine, H-7, and H-89), 
PTP1B (Na3VO4, and TCS-401), HDAC3 (TSA), Sirt1 (EX527) and a Sirt1 
activator (SRT1720). For PAD4 assay, CaCl2 titration (0.5, 1.0, and 5.0 mM) was 
performed using GSK484 (5 µM) as a negative control. The assay conditions are 
shown in Table 6. Additionally, the peptide-break technology was demonstrated 
for kinetic measurements in PKA and EGFR assays using 20 μl final volume. In 
the PKA assay, 2 nM Ser-LZ peptide, 1 nM Eu3+-LZ, and 1.5 μM MT2 quencher 
were incubated for 5 min. Next, a mixture of 1 nM PKA and 50 μM ATP was 
added to start the enzymatic reaction and the direct TRL-signal measurement (“0-
time point”). The EGFR assay was performed using 8 nM Tyro-LZ, 1 nM EGFR, 
50 μM ATP, 3 nM Eu3+-LZ, and 1.5 μM MT2 in the same manner. 
 
Inhibitor screening assay using the PKIS library was performed to validate the 
approach. Before the screen, EGFR and PKA assay miniaturization was performed 
from 50 to 10 µl final volume. DMSO tolerance was studied with varying DMSO 
concentrations (0-10%) in the 10 μl miniaturized assay. The assay conditions were 
10 nM peptide, 50 μM ATP, and 0.5 nM PKA/1 nM EGFR. For detection, 10 
nM/5 nM Eu3+-LZ and 3 μM/2 μM MT2 quencher were used in PKA/EGFR 
assays. The screening assays used 356 compounds from the Published Kinase 
Inhibitor Set (PKIS) library in a single data point (1 μM) for each compound. 
Also, 96 points for 0 and 1 μM of staurosporine were used as controls and to 
measure the assay robustness (Z' factor) from the three assayed plates. 
4.5.2 The peptide-break technology using the charge-based peptides (III) 
Substrate peptide selection. First, a homogeneous QRET binding assay was 
performed to define the optimal charge and affinity for the charge-based (CP) 
peptides. In the assay, CP1-3 and Ser-LZ peptides (10 nM) were tested with Eu3+-
LZ detection peptide (10 nM) and MT2. Next, a homogeneous QRET enzymatic 
assay with PKA kinase, H-89 inhibitor (0 and 2 μM), and CP1-3 and Ser-LZ 
peptides was performed to obtain assay window between modified and non-
modified peptide. The assay conditions are shown in Table 6. Later, binding tests 
with CP-peptides for citrullination (CP4/CP5) and deacetylation (CP6/CP7) and the 
same detection component were performed to optimize the assays. 
 
Homogeneous PTM enzymatic assays. Inhibitor titrations (0-25 µM) were 
performed against PKA, PIM1-3, PAD4, and HDAC3 enzymes to validate the 
assays. H-89 and staurosporine inhibitors were used in the PKA assay, while 
staurosporine in the PIM1-3 assays, both assays with CP1 peptide. The PAD4 
 
53 
assays used CP4 and Arg-LZ peptides and GSK484 inhibitor. The HDAC3 assay 
used CP6 and LysAc-LZ peptides and TSA inhibitor. The assay conditions are 
shown in Table 6. 
 
Detection peptide selection was performed using binding and enzymatic assays. 
Different charged detection peptides, Eu3+-CPR1 and Eu3+-CPR2, and a LZ-
detection peptide Eu3+-LZ were studied with CP1-3. The assay conditions are 
shown in Table 6. 
4.5.3 The thermal dissociation assay using the peptide-break technology 
(IV) 
Homogeneous thermal dissociation assay was performed to measure the thermal 
detachment profile of the peptide dimers. LZ-peptides for dephosphorylation (LZ-
Y/LZ-pY), CP-peptides for deacetylation (CP6/CP7) and demethylation 
(CP8/CP9), and Eu3+-LZ detection peptide were used in the experiments. In the 
assay, substrate peptides (10 μM) and a mixture of Eu3+-LZ (1 nM) and MT10 
(0.5 mM) were added to a 96-well plate and incubated 5 min. Next, the plate was 
heated from 25 °C (RT) to 90 °C using a thermal cycler, and the TRL-signal was 
recorded every 5 °C with a 3 min incubation at the chosen temperature. Later, a 
thermal binding assay using different ratios of phosphorylated (LZ-pY) and non-
phosphorylated (LZ-Y) peptides and Eu3+-LZ (1 nM) was performed to understand 
the assay sensitivity. In the assay, LZ-Y peptides were added to the LZ-pY solution 
in varying percentage (0, 0.5, 1, 5, 7, and 100%) keeping a 10 μM final 
concentration of LZ-Y and LZ-pY in the well. 
 
PTM enzymatic monitoring using the thermal dissociation assay. Inhibitor 
titrations (0-1 µM) were performed against PTP1B and HDAC3 enzymes using 
Na3VO4 and TSA inhibitors, respectively. The enzymatic assay was performed as 
previously described. Assay conditions are shown in Table 6. Additionally, a 
thermal dissociation assay using single-flash heating was performed to increase the 
assay throughput. The optimal temperature was reached using a single flash 
heating, and the plate was kept 3 min at it before the measurement. The Z' factor 
was determined for PTP1B and HDAC3 assays using 18 positive and 18 negative 
controls (Na3VO4 and TSA at 5 µM). 
 




5 RESULTS AND DISCUSSION 
The studies presented from this doctoral thesis were focused concentrated on the 
development of a universal detection method for PTM enzymatic assays using the 
QRET technique in an antibody-free and HTS-compatible format. A summary of 
the results and discussion of publications I-IV is presented here. 
The QRET technique is a detection method that has previously demonstrated 
its potential for HTS assays. It was first presented for receptor-ligand interaction 
screening assays in 2009 (Härmä et al. 2009) and successfully developed for other 
applications (Kopra & Härmä 2015). The simplicity of the method relies on its 
single-label approach and easy assay set-up, while its sensitivity is based on the use 
of the time-gated monitoring. This combination makes QRET a viable option for 
the development of PTM enzyme assays. 
In this thesis, the main goal was to develop a universal detection platform for 
PTM enzyme activity monitoring using the QRET technique. The universal 
method, called the peptide-break technology, would be simple, sensitive, and 
versatile, allowing the monitoring of a wide range of different PTM types. Before 
proceeding with the peptide-break technology development, the QRET suitability 
for PTM monitoring was first evaluated in a homogeneous tyrosine EGFR assay 
(I). The developed assay used antibodies to recognize the modified substrate 
peptide, which is a commonality in FRET, however in a single-label approach. On 
the basis of this, the peptide-break technology was further developed and optimized 
using QRET and a peptide-peptide binding approach. The approach was based on 
the leucine zipper (II) and electrostatic interaction (III) concepts, which allowed 
the use of concentrations in the nanomolar range. In the last stage of the project, 
the peptide-break technology was applied to a thermal dissociation assay allowing 
the use of substrate peptide concentrations in the micromolar range (IV). 
5.1 The QRET technique in a homogeneous EGFR kinase 
assay (I) 
In publication I, a homogeneous QRET tyrosine EGFR kinase assay was 
introduced using a Eu3+-chelate conjugated substrate peptide and a phosphotyrosine 
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specific antibody (Figure 13). The QRET technique distinguishes between the 
non-phosphorylated Eu3+-peptide and the antibody bound to the phosphorylated 
Eu3+-peptide in the presence of soluble quencher molecules. 
 
Figure 13. The principle of the homogeneous single-label epidermal growth factor 
receptor (EGFR) activity assay. Upon phosphorylation, a specific antibody binds to 
the phosphotyrosine Eu3+-peptide and simultaneously protects the Eu3+-chelate 
from quenching, resulting in a high TRL-signal. Conversely, in an inhibited 
reaction, the non-phosphorylated Eu3+-peptide is preferentially quenched by the 
quencher molecules (Q) leading to low TRL-signal. Figure from the original 
publication I. 
 
Three different peptides with phosphotyrosines at positions -2, -3 or -4 (PEP4-6) 
from the amino-terminal Eu3+-chelate (Table 5) were designed to study the optimal 
Eu3+-chelate protection from the antibody recognition. In the QRET binding assay, 
no significant differences between the peptides were found. All phosphotyrosine 
positions protected equally the Eu3+-chelate from quenching after antibody 
recognition, yielding an averaged S/B of five. Despite this, the orientation or the 
proximity of the Eu3+-chelate with regards to the phosphorylation site could 
interfere with the EGFR ability to phosphorylate. In this sense, PEP1-3 peptides 
were studied in a QRET enzymatic assay using the EGFR catalytic domain. The 
substrate peptide with the furthest tyrosine position (-4) (PEP 1) from the Eu3+-
chelate, showed the best S/B=4. This may be due to the increased distance between 
Eu3+-chelate and tyrosine position providing less interference in the 
phosphorylation reaction and detection. PEP1 was selected to optimize the enzyme 
and antibody concentrations. 
 The utilized EGFR catalytic domain had multiple phosphotyrosine sites, which 
were found to increase the required antibody concentration in the assay. The 
relation between antibody and EGFR concentration was studied in titration assays. 
From these assays, a higher antibody concentration was required in the presence of 
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constant EGFR (2 nM) and phosphorylated peptide (10 nM) compared to assays 
without EGFR (Figure 14A). This was since the antibody recognizes equally all 
phosphotyrosines and not only the ones in the Eu3+-peptide. Next, an EGFR 
titration assay was performed using 10 nM of phosphorylated peptide and 40 
ng/well of antibody in a heterogeneous format to rule out the potential QRET 
effect. It was found that the antibody interaction with the phosphorylated Eu3+-
peptide was completely blocked at 25 nM EGFR concentration (Figure 14B). In 
this regard, about 5-fold higher antibody concentration (187 ng/well) was utilized 
for subsequent assays. 
Figure 14. The relation between epidermal growth factor receptor (EGFR) and 
4G10 antibody concentrations. (A) In a QRET assay with phosphorylated Eu3+-
peptide (PEP 4), the anti-phosphotyrosine antibody was titrated without EGFR 
(square) and with EGFR (circle) in the presence of ATP. (B) EGFR was titrated in 
the presence of PEP 4 and the antibody in a heterogeneous assay. Increasing the 
EGFR concentration increments also the number of available phosphotyrosine 
sites, thus diminishing the antibody binding to PEP 4. Data are the means ± SD 
(n=3).  Figure modified from publication I. 
 
In an antibody-based EGFR assay, high kinase concentrations would lead to high 
antibody concentrations, increasing the overall assay cost. In this regard, an EGFR 
titration was performed in a QRET enzymatic assay to assess the assay sensitivity. 
In the assay, the best S/B ratio was 3.9 achieved with 2 nM of EGFR, while 5 nM 
EGFR gave a S/B of 1.9, due to the increased antibody binding to the enzyme 
phosphotyrosines. In the assay using 2 nM EGFR, the degree of phosphorylation 
was approximately 70% of the total substrate peptide (calculated by comparing the 
TRL-signals of the synthetically phosphorylated peptide control under equal 
conditions, in the presence of EGFR and antibody). Validation of the developed 
assay was demonstrated using 2 nM of EGFR with a small panel of known ATP-
competitive EGFR inhibitors with different potencies in the pico-to-nanomolar 
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range (Figure 15). The monitored IC50 values ranged between 0.08 and 155 nM 
with a S/B between 3.0 to 4.3. 
In publication I, the suitability of QRET for enzyme activity monitoring in an 
antibody-based system was studied and proven. In the reported kinase assay, the 
substrate peptide was labeled with Eu3+-chelate, and the phosphorylated peptide 
was detected by using a specific antibody. In all the antibody-based methods, the 
need for specific antibodies limits the applicability of the approach to other PTM 
types. 
 
Figure 15. Dose-response curves for epidermal growth factor receptor (EGFR) 
inhibitors using the optimized QRET antibody-based kinase assay. The inhibitors 
were titrated from 0 to 5 µM concentration. Data are the means ± SD (n=3). Figure 
from publication I. 
 
Antibody-based detection assays have been successfully developed for certain 
PTMs like tyrosine phosphorylation (Seethala & Menzel 1997; Varkondi et al. 
2005; Degorce et al. 2009; Horton & Vogel 2010). Since the anti-phosphotyrosine 
antibodies are relatively insensitive to the surrounding AA context, they are 
broadly reactive. However, phosphoserine or phosphothreonine antibodies require 
a specific AA sequence surrounding the binding site, thus limiting the diversity of 
phosphorylated sites being recognized (Li et al. 2008). Also, developing pan-
specific antibodies can be challenging for small size PTMs, as they are poorly 
antigenic (Zhao & Jensen 2009). In general, an antibody would have to be 
generated for each tested substrate peptide, which may also be time-consuming and 
expensive. The dependency on suitable antibodies limits the reported QRET kinase 
assay. Additionally, when extrapolating the system to other PTM types, the 
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conjugation of a Eu3+-chelate for every tested peptide would have to be performed. 
Considering controls and additional peptides for assay optimization would mean a 
tremendous amount of work and an expensive approach. This work has proven the 
functionality of QRET in a PTM enzymatic assay. The assay is potentially 
applicable to other kinases with a substrate peptide containing a suitable sequence 
for the studied kinase and a specific antibody for the phosphopeptide detection. 
However, having an antibody-based detection system with a substrate peptide 
being labeled for every enzyme studied does not resemble the best approach for a 
universal PTM enzymatic assay. 
5.2 The peptide-break technology as a universal detection 
method for a wide spectrum of PTMs (II, III, IV) 
As challenging new targets are emerging, new screening strategies should also be 
raised to fill the unmet HTS technology needs. While antibody-based detection 
assays provide a sensitive system for enzyme activity monitoring, there are limiting 
factors related to the availability of suitable antibodies for the desired targets. 
Antibody-free methods have been developed such as IMAP (Loomans et al. 2003), 
or Omnia (Shults & Imperiali 2003), which have been actively developed for 
kinases, but the nature of its approach has limited expandability to other PTM 
types. Other technologies, such as Transcreener, LANCE, or AlphaScreen, have 
been able to provide tools for a more extended PTM set, e.g., kinases, 
methyltransferases, and deacetylases, although at the cost of having a detection 
system which depends on antibodies or enzyme cascades.  
The peptide-break technology was developed using QRET and a peptide-
peptide binding approach in an antibody-free detection system. The binding 
approach was based on the leucine zipper (II) and electrostatic interaction (III) 
concepts, which were optimized to be used in the nanomolar range concentrations. 
Later, the peptide-break technology was applied to a thermal shift assay, which 
allowed the use of substrate peptide concentrations this time in the micromolar 
range (IV). 
5.2.1 The peptide-break technology using the leucine zipper approach (II) 
Leucine zippers (LZ) are coiled-coil dimerization domains of the basic-region 
leucine zipper (bZIP) transcription factor proteins. These bZIP proteins are 
regulators of cellular processes including cell proliferation, tissue differentiation, 
and the response to oxygen or AA deprivation (Kaplan et al. 2014). Their activities 
depend on the specific DNA recognition and the stability and specificity of protein 
dimer formation (O’Shea et al. 1991). The LZ motifs mediate protein dimerization, 
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which is required to promote DNA binding and subsequently influence the RNA 
synthesis rate (Daugherty & Gellman 1999). In vitro studies have shown that LZ 
sequences between only 30 to 40 residues are sufficient for coiled-coil 
heterodimeric formation (O’Shea et al. 1991), having KD values ranging from pM 
to high µM (Daugherty & Gellman 1999; Kaplan et al. 2014). The LZ sequences 
are arranged by heptad repeats denoted as (abcdefg)n, where a and d are usually 
hydrophobic residues, with leucines in d positions. The e and g positions are 
usually long, charged or polar amino acids that contribute to the electrostatic 
interactions. The remaining positions b, c, and f are located at the surface, away 
from the coiled coil (Daugherty & Gellman 1999; Kaplan et al. 2014) (Figure 
16A).  
In the peptide-break technology, a LZ dimer is formed by a Eu3+-labeled 
detection peptide and the substrate peptide designed for the studied enzyme. The 
LZ dimer formation leads to Eu3+-chelate protection and a high TRL luminescence 
signal, while the addition of a PTM to the substrate peptide leads to dissociation of 
the peptide dimer enabling signal attenuation from the soluble quenchers. The 
peptide pair re-associates when the PTM is cleaved from the substrate peptide 
providing a method to investigate transferases and hydrolases (Figure 16B). 
 
Figure 16. The principle of the universal peptide-break technology and leucine 
zipper interaction. (A) In the LZ dimer structure, d-positions are occupied with 
leucines and typically a-positions with hydrophobic amino acids. Positions e and g 
contain typically charged residues contributing to the binding. (B) In the peptide-
break technology, a high TRL-signal is detected upon leucine zipper (LZ) dimer 
formation, and dimer detachment due to a PTM addition promotes luminescence 
quenching. Figure modified from publication II. 
 
The highly characterized LZ from the Fos and Jun proteins, which form the 
heterodimeric complex AP-1 transcription factor, was used as a starting point for 
the assay development (Kaplan et al. 2014). Jun and Fos sequences of 36 AA 
length from the LZ domain were selected to serve as substrate peptide and 
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that the Jun/Fos pair formed a typical helical structure, while the helical structure 
was lost for the p-Jun/Fos pair, giving a 222 nm/208 nm ratio of 0.89 and 0.56, 
respectively (Figure 17A). This corroborated that the PTM presence in the 
substrate peptide is able to destabilize the peptide dimer helicity. Homogeneous 
binding assays showed an EC50 value of 2.5 µM for the Jun/Fos, while no binding 
was detectable under the tested conditions for the p-Jun/Fos pair (Figure 17A, 
inset). On this basis, higher affinity peptides were designed to enable the 
measurement of PTMs with higher sensitivity by shifting the peptide break-down 
point to nanomolar concentrations. This was a critical point in the assay 
development, as the new peptides should have optimal peptide-pair binding with 
sufficient affinity and dissociation properties. Helicity studies of the redesigned 
peptides, tyrosine phosphorylated (TyroP-LZ), non-phosphorylated (Tyro-LZ) and 
detection peptide (EuLZ), indicated substantial helicity for both dimers Tyro-
LZ/EuLZ and TyroP-LZ/EuLZ at 30 µM, giving a 222 nm/208 nm ratio of 0.75 
and 0.77, respectively (Figure 17B). Higher affinity binding was indeed achieved 
as even the phosphorylated residue in the TyroP-LZ/EuLZ dimer was unable to 
destabilize the typical helical structure when using 30 µM of peptides. 
 
Figure 17. Structural and binding studies of phosphorylated and non-
phosphorylated LZ peptides. (A) CD spectra of Jun/Fos and p-Jun/Fos dimers at 30 
µM show no helicity for the phosphorylated p-Jun/Fos dimer, (B) while CD spectra 
of Tyro-LZ/EuLZ and TyroP-LZ/EuLZ dimers at 30 µM indicate substantial 
helicity for both dimers. Homogeneous QRET binding tests for all the peptide pairs 
are shown in the insets. Figure modified from publication II. 
 
The homogeneous binding assays gave EC50 values of 0.3 µM and 0.006 µM for 
the TyroP-LZ/EuLZ and the Tyro-LZ/EuLZ pair, respectively (Figure 17B, inset). 
The EC50 value differences between the phosphorylated and non-phosphorylated 
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pair provide the basis to measure PTMs at nanomolar level with a suitable assay 
window.     
The functionality of the peptide-break technology was first tested with a small 
panel of selective and non-selective inhibitors against EGFR and PKA kinases. 
Later, the universality of the technology was studied using PTP1B phosphatase, 
PAD4 amidinotransferase, Sirtuin 1 and HDAC3 deacetylases (Figure 18). 
Substrate peptides were designed for each studied enzyme considering the required 
consensus sequences and the LZ sequences to maintain the binding with the 
detection peptide. The obtained IC50 values were comparable to the literature 
values, and the S/B ratios ranged between 4–97. The generated data proved the 
versatility of the assay, indicating potential applicability to other PTMs using this 
single-label and antibody-free approach. Additionally, the peptide-break 
technology was further adapted to a real-time kinetic mode using the 
phosphorylation developed assays for EGFR and PKA kinases. The adapted 
method applies to a continuous signal reading as previously demonstrated in 
QRET-based assays (Kopra et al. 2014a, 2014b). 
 
Figure 18. Dose-response curves for inhibitors and an activator against the studied 
enzymes. Compounds were run against (A) PTP1B phosphatase, (B) PAD4 
amidinotransferase at varying CaCl2 concentrations, (C) HDAC3 deacetylase, and 
(D) Sirtuin1 deacetylase. Typical sigmoidal curves are shown in the figures. Data 
represent the means ± SD (n=3). Figure modified from publication II. 
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Assay validation was performed by running a small-scale HTS screen with 356 
compounds of the PKIS library against EGFR and PKA kinases. Before the 
screening, DMSO tolerance was evaluated in a 10 µl miniaturized assay, showing 
tolerance of 10% DMSO. From the screening, 10/13 PKA inhibitors (Figure 19A) 
and 42/48 EGFR inhibitors (Figure 19B) were found with IC50 values lower than 1 
µM. Assay robustness was investigated during the PKA screen, and an average Z' 












Figure 19. Validation of the universal peptide-break technology using the PKIS 
library in PKA and EGFR kinase assays. The screening was performed at 1µM 
compound concentration and a (A) 3SD threshold for hit identification was set for 
PKA and a (B) 6SD threshold for EGFR assays. The number of detected 
compounds are comparable with the Nanosyn Caliper screening information found 
in the literature (Elkins et al. 2016). The S/B ratio was 12 and 6 for the PKA and 
EGFR kinase assays, respectively. Figure modified from publication II. 
 
In publication II, a simple, sensitive, and versatile luminescent assay was reported, 
which enabled the monitoring of small-size PTMs. The key benefit of the peptide-
break technology relies on its versatility. The assay development is simple as the 
detection peptide sequence remains the same regardless the substrate peptide 
sequence of the studied enzyme. Using this approach, it could be assumed that any 
PTM could be measurable. However, inserting a consensus sequence in the LZ 
peptide can present a great challenge in the peptide design. The leucines located at 
d-positions, which are spaced 7 residues apart along an α-helix and the coiled-coil 
interface of the LZ, have to be conserved to provide sufficient peptide-peptide 
binding affinity (Daugherty & Gellman 1999; Kaplan et al. 2014). Simultaneously, 
the modifiable AA should provide sufficient dissociative properties only upon 
PTM addition. These challenges lead to the following studies reported in the 




5.2.2 The peptide-break technology using the charged peptides approach 
(III) 
While some enzymes are insensitive to the peptide sequence context they modify, 
other enzymes may require specific amino acids flanking the modification site for 
substrate peptide recognition (Bheda et al. 2016). For example, enzymes such as 
O-GlcNAc glycotransferases (OGTs), which glycosylate serine or threonine, 
require specific amino acids such as proline, which is known to be the most 
sterically restricted of all the amino acids (Pathak et al. 2015). Proline gives 
conformational rigidity to the peptide sequence, which would disrupt the LZ dimer 
coiled-coil structure in the peptide-break system. This would result in loss of the 
dimer formation between the substrate peptide and the detection peptide, thus, 
limiting the use of the technology for this enzyme target. 
In publication III, we introduced the peptide-break technology based on a 
peptide dimerization utilizing electrostatic interactions between oppositely charged 
peptides. In the system, the affinity of the peptide dimer required optimization to 
obtain dimer dissociation upon PTM addition. There was no need to maintain a 
leucine in a specific position, and the coiled-coil structure was not required for 
peptide-peptide binding. Since only the overall peptide charge gives the basis of 
peptide dimerization, the freedom for enzyme substrate peptide selection was 
increased. Charge-based (CP) peptides were studied using sequences without 
leucines, and the optimal peptide architecture was adjusted in PKA- and PIM-
mediated serine phosphorylation assays. After that, the concept was tested in 
arginine citrullination and lysine deacetylation assays. Three substrate peptides 
(CP1-3) with two phosphorylation sites, varying length (19 to 34 residues), and 
different charges (+10 to +23) were designed for PKA activity monitoring (Table 
5). The CP1-3 affinities were studied by their binding to the previously described 
Eu3+-LZ detection peptide, which was negatively charged, and compared to the LZ 
substrate peptide (Ser-LZ) for PKA kinase (II). Binding assays using 10 nM of 
peptide showed that the affinity of the duplex formation followed the order of the 
positive charge of the substrate peptide (Figure 20A). 
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leucines, and the optimal peptide architecture was adjusted in PKA- and PIM-
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arginine citrullination and lysine deacetylation assays. Three substrate peptides 
(CP1-3) with two phosphorylation sites, varying length (19 to 34 residues), and 
different charges (+10 to +23) were designed for PKA activity monitoring (Table 
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Figure 20. Binding and functionality properties of the charge-based (CP) and 
leucine zipper-based peptides. (A) The affinity of the CP-peptides was determined 
against Eu3+-LZ, and compared to Ser-LZ for PKA kinase. The affinity of the 
peptides was in order CP3 >> CP2 > Ser-LZ > CP1. (B) Enzymatic PKA assay 
with CP and LZ peptides was performed to obtain assay window between modified 
and non-modified peptide. The lowest binding affinity (CP1) provides the highest 
separation after PTM addition. Data represent the means ± SD (n=3). Figure from 
publication III. 
 
Based on the data, a net charge between +10 (CP1) and +13 (CP2) in the CP-
peptide is needed to obtain the binding affinity comparable to the Ser-LZ control 
with Eu3+-LZ. The longest peptide, CP3 (+23), showed ultra-high affinity in 
binding compared to Ser-LZ. Since the phosphorylated residues may not be able to 
disrupt this high-affinity complex formed with Eu3+-LZ, CP3 was not expected to 
be functional in the enzymatic assays. In the PKA kinase assay, the highest S/B 
ratio was obtained with the 19 AA CP1 (S/B=30) (Figure 20B), which showed the 
lowest affinity in binding to Eu3+-LZ reporter (Figure 20A). This pair gave an S/B 
ratio comparable to the control LZ-pair (S/B=26). The two phosphorylated sites on 
CP1 seemed to disrupt the peptide dimer efficiently, allowing sufficient TRL-
signal quenching and thus a low background. CP2 and CP3 peptides also showed 
high binding levels after phosphorylation, leading to lowered peptide-pair 
dissociation efficiency with S/B ratios of 7.7 and 1.2 for CP2 and CP3, respectively 
(Figure 20B). This points out that the substrate peptide design should be optimized 
considering the peptide affinities and the characteristics of studied PTM, as small-
size PTMs such as methylation (Hamamoto et al. 2015) may not disrupt a high-
affinity dimer. Based on these results, CP1 was selected for further assay 
functionality studies in dose-response measurements using PKA kinase and three 
PIM family kinase assays. In the inhibitor titrations, both PKA and PIM assays 




The concept was also tested in citrullination and deacetylation assays using CP 
and LZ peptides side-by-side. Based on CP1, CP-peptides were selected for PAD4 
(citrullination) and HDAC3 (deacetylation) assays containing two modification 
sites and keeping the +10 charge and 19 AA-length of CP1 (Table 5). Similar S/B 
ratios were obtained between the binding and enzymatic assays for both PTMs 
using the negatively-charged Eu3+-LZ detection peptide (Figure 21A), confirming 
the correct assay functionality. Later, the assay validation was performed in dose-
response assays. The obtained IC50 values were comparable between the CP- and 
the LZ peptide assays and the S/B ratios range between 6 and 8 for all the assays 
(Figure 21B). 
Figure 21. Binding and functionality properties of the charge-based citrullination 
and deacetylation peptides. (A) Similar S/B ratios were obtained between binding 
(plain bars) and enzymatic (stripped bars) assays for citrullination and 
deacetylation. (B) Inhibitor titrations against PAD4 and HDAC3 enzymes gave 
characteristic sigmoidal curves. GSK484 titration was performed for citrullination 
with the CP4 (squares) and Arg-LZ (circles) peptides, while TSA titration for 
deacetylation with CP6 (triangles) and LysAc-LZ (dotted line). Similar IC50 values 
were obtained between the CP- and LZ-peptides.  Data represent the means ± SD 
(n=3). 
 
Additionally to the substrate peptide studies, charge-based detection peptides were 
studied with CP1-3 substrate peptides. The 36 AA-length of the previously studied 
Eu3+-LZ detection peptide was necessary for dimerization. However, as the CP-
peptides bind through electrostatic interactions, the net charge is crucial and not the 
peptide length. Besides, the CP1-3 substrate peptides contained 19 AA, with which 
a 36 AA-length detection peptide was not needed. Two negatively-charged Eu3+-
peptides of 15 AA (Eu3+-CPR1) and 27 AA (Eu3+-CPR2) were studied using the 
CP1-3 peptides in binding and enzymatic PKA assays. No differences in the 
binding affinity were found within the CP1-3 peptide series and the Eu3+-CPR2 due 
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to the apparent high affinity of the peptide (-23). However, the affinity increased 
with the increasing positive charge of the substrate peptide with the 15 AA Eu3+-
CPR1 (-12). In the PKA assays, the CP1/Eu3+-CPR1 pair gave S/B=8.9, while the 
CP2/Eu3+-CPR1 pair gave S/B=3.6. The higher affinity of CP2 compared to CP1 
showed decreased separation between phosphorylated and non-phosphorylated 
peptides, while the ultra-high affinity of CP3 prevented any PTM dependent 
separation (S/B=1).  
These data demonstrate that with CP-peptides the sequence length can be 
significantly reduced without losing the required affinity or assay window between 
modified and non-modified peptides, which is not possible when using LZ 
peptides. The CP peptides can be easily modified as they are not restricted to 
specific amino acids in certain positions or to a structural conformation, but the 
peptide net charge is crucial. In this sense, the peptide affinity can be adjusted by 
simply changing the number of charges in the peptide and their distribution. This 
versatility provides to the peptide-break technology the possibility of extrapolating 
the system from one PTM to another, as in the case of phosphorylation, 
deacetylation and citrullination assays (III). Working with charged peptides could 
bring some disadvantages. Charged molecules present in the assay would 
potentially bind to the oppositely charged peptides. However, we have not 
observed those interferences in the reported assays. The labeled detection peptide 
binds to the substrate charged peptide with high affinity. Additionally, charged 
amino acids in the substrate peptide could negatively affect the substrate 
recognition by the enzyme, if the enzyme is highly dependent on a consensus 
sequence. But working with high-affinity substrate peptides and in high 
concentration would perhaps favor the peptide recognition. More studies on the 
charged-based system would be needed to know its limitations and disadvantages. 
However, this system shows so far the advantage of higher freedom to modify the 
substrate peptide and brings options for detection, as the Eu3+-peptides can be 
selected freely. 
5.2.3 A luminescence thermal dissociation assay using the peptide-break 
technology (IV) 
The thermal shift assay (TSA) is a biophysical method applied to drug discovery as 
well as structural studies (Redhead et al. 2017). TSA for drug discovery relies on 
the stabilization of the complex formed by an interaction such as a ligand and a 
protein. By increasing the unfolding temperature, a fluorescence signal change is 
monitored in the presence of a fluorescent dye sensitive to protein denaturation 
(Scott et al. 2016). The ligand-binding affinity is estimated by the change of the 
unfolding temperature detected in the presence and absence of the ligand. A 
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fluorescence-based TSA has been proposed as an easy-to-develop method for hit 
identification compared to other biophysical methods (Lo et al. 2004). It can be 
performed using a standard thermal cycler instrument for PCR and a plate reader 
for fluorescence monitoring. 
In publication IV, the peptide-break technology was applied to a luminescence 
TSA that harnessed the thermal stability difference of the post-translationally 
modified and non-modified peptide dimer (Figure 22). A high peptide 
concentration forces peptide dimerization independent of the PTM presence 
(Figure 17B), and the PTM addition reduces the affinity between dimer-forming 
peptides. In the luminescence TSA approach, the peptide dimer stability decreases 
at elevated temperature, being less stable the dimer with a PTM. As a result, higher 
TRL-signals are detected for the peptide dimer without a PTM. 
 
 
Figure 22. The principle of the thermal dissociation assay using the peptide-break 
technology. At room temperature, high peptide concentration drives the peptide 
dimerization irrespective of the PTM presence. As the PTM induces dimer 
disruption, the affinity between the dimer-forming peptides with a PTM (blue line) 
is lower than the dimer without a PTM (orange line). At the optimal temperature, 
the dimer with a PTM is disrupted allowing signal attenuation due to the quenchers 
in solution, while the non-modified dimer remains intact resulting in Eu3+-chelate 
protection and high TRL-signal. 
 
The peptide-break approach was evaluated for the TSA using LZ- and CP-peptides. 
The thermal profile of the non-modified LZ-Y and phosphorylated LZ-pY with 
Eu3+-LZ showed an increase in the monitored S/B ratio being 2.5 at RT and 36 at 
70 °C (Figure 23A). This demonstrated that there was PTM-independent binding 
of the peptides at RT when 1.5 nM Eu3+-LZ and 10 µM substrate peptide were 
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The peptide-break approach was evaluated for the TSA using LZ- and CP-peptides. 
The thermal profile of the non-modified LZ-Y and phosphorylated LZ-pY with 
Eu3+-LZ showed an increase in the monitored S/B ratio being 2.5 at RT and 36 at 
70 °C (Figure 23A). This demonstrated that there was PTM-independent binding 
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used. However, at 70 °C, the LZ-pY/Eu3+-LZ dimer stability was lower than the 
stability of the LZ-Y/Eu3+-LZ. As a result, a difference in the recorded 
luminescence signals was observed due to the presence of the quenchers which 
lead to a high S/B ratio. The assay sensitivity was evaluated using LZ-pY and LZ-
Y peptides in different ratios keeping the overall peptide concentration to 10 µM. 
At 70 °C, 1% (100 nM) of the non-phosphorylated dimer was detected from the 
phosphorylated population giving a S/B=7 (Figure 23B). The peptide-break 
technology was optimized for PTM monitoring in the nanomolar range to increase 
the assay sensitivity. Micromolar concentrations of the peptides in the assay forces 
peptide dimerization independent of the PTM presence. Using temperature-induced 
dimer disruption allowed the use of peptide concentrations in the micromolar range 
and detection of nanomolar concentrations of the modified substrate peptide. 
 
Figure 23. Thermal dissociation response of the leucine zipper (LZ)- and charge 
based (CP)-peptides. (A) The thermal profile of the LZ-Y/LZ-pY peptides for 
dephosphorylation showed an optimal temperature of 70 °C, while the CP-peptides 
profile showed 50 °C for deacetylation (CP7/CP6) and 45 °C for demethylation 
(CP9/CP8) using 10 µM of substrate peptides and 1.5 nM Eu3+-LZ in the system. 
(B) The thermal assay sensitivity was evaluated using different ratios of LZ-pY and 
LZ-Y peptides considering 10 µM total concentration. At 70 °C, less than 1% (100 
nM) of non-phosphorylated peptide LZ-Y was detected from the 10 µM LZ-pY 
pool with a S/B=7. Data are shown as means ± SD (n=3). Figure modified from 
publication IV. 
 
The TSA was tested for deacetylation and demethylation using CP6/CP7 and 
CP8/CP9 peptides, respectively. The thermal profile showed that the optimal 
temperature for demethylation and deacetylation was 45 °C (S/B=5.1) and 50 °C 
(S/B=10.5), respectively (Figure 23A). Comparing the optimal temperatures 
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between the CP- and LZ-peptides, indicated that a higher temperature is needed to 
affect the LZ dimer (70 °C). This difference may be explained by the different 
binding mechanisms and differential affinity of the peptide pairs. The apparent 
stability of the LZ dimer against thermal-induced dimer disruption is greater than 
the CP dimer stability. The LZ dimer formation is based on a specific binding 
through leucines and electrostatic interactions (Kaplan et al. 2014), while the 
charged peptide dimerization is based on non-specific electrostatic interaction. The 
quenching effect is crucial to obtain the S/B ratio, since no differences were 
observed when the thermal profiles were measured without the quencher. 
The TSA was tested for enzyme activity monitoring using PTP1B for 
dephosphorylation and HDAC3 for deacetylation. In the dephosphorylation assay, 
a maximal S/B ratio of 25 was monitored at 70 °C (Figure 24A), while in the 
deacetylation 3.8 was monitored at 55 °C (Figure 24B). In the case of CP-peptides, 
the thermal curve had a broader maximum, which was observed in both synthetic 
and enzyme-catalyzed reactions. This may be a thermal profile proper of the CP-
peptides as this was not observed with the LZ-peptides. 
 
Figure 24. Enzymatic dephosphorylation and deacetylation assays using the 
thermal shift based peptide-break technology. (A) Dephosphorylation assay using 
LZ-pY and Eu3+-LZ peptides gave a S/B=25 at 70 °C, while (B) deacetylation 
assay using CP6 and Eu3+-LZ showed a broad peak in the temperature profile being 
optimal at 55 °C with a S/B ratio of 3.8. Data are shown as the means ± SD (n=3). 
Figure modified from publication IV. 
 
The thermal dissociation assay was validated by performing dose-response 
measurements for inhibitors against the studied enzymes. The calculated IC50 
values were 3.8 nM for Na3VO4 and 9.1 nM for trichostatin A, used to inhibit 
PTP1B and HDAC3, respectively. The monitored values were in line with the 
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published literature (Gordon 1991; Muthyala et al. 2015). Additionally, the 
proposed system was tested using single temperature flash heating. This protocol 
was expected to be better suited for HTS, as only 3 min at the selected temperature 
was needed to induce the separation between modified and non-modified peptides. 
Z' factor values > 0.6 were monitored with the flash-heating for both enzymatic 
assays. 
The QRET-based thermal dissociation assay using the peptide-break 
technology was presented as a proof-of-principle for dephosphorylation and 
deacetylation enzymatic assays, but could potentially be applied to other PTM 
types. The assay enabled the use of high substrate peptide concentrations (µM 
range) to enable the monitoring of low activity or affinity enzymes. Enzymes with 
low activity are challenging to measure as low concentrations of the modified 
product are produced. In this sense, a high peptide concentration would enable the 
full enzyme activity. The majority of the TSA applications have been focused on 
ligand-binding affinity studies. In drug discovery, TSA can be used to identify 
compounds that bind to a protein and stabilize it against thermal denaturation 
(Redhead et al. 2017). In this project, TSA for enzyme activity monitoring was 
developed using the peptide-break technology. The method can use µM 
concentrations of substrate peptides and detect nM concentrations of the post-





















Nowadays, the available HTS technology offers several options for the drug 
discovery and development community to select methods that better suit their 
goals. However, the current technologies are not yet adaptable to the emerging 
complex targets. There is a demand for new screening strategies and versatile 
technologies capable of addressing the novel targets issues. 
The doctoral study concentrated on the development of a universal detection 
platform for PTM monitoring using the QRET technique in an antibody-free 
system. All the assays were constructed using Eu3+-chelates in a single-label 
approach and HTS compatible format. The suitability of QRET for PTM 
monitoring was first evaluated in a conventional homogeneous EGFR kinase assay 
(I) using antibodies to recognize the modified substrate peptide. On the basis of 
this the peptide-break technology was further developed using an antibody-free and 
peptide-peptide binding approach. This was assessed based on the leucine zipper 
(II) and electrostatic interaction (III) concepts, which allowed the use of 
nanomolar concentrations in the assays. In the publication IV, the peptide-break 
technology was applied to a thermal shift assay, allowing the use of peptide 
concentrations now in the micromolar range. 
 
The main conclusions based on the original publications are: 
 
I  In this article, the suitability of QRET for PTM enzymatic monitoring was 
demonstrated in a phosphorylation assay. Although, as with FRET assays in 
general, an antibody (anti-phosphotyrosine) was used for detection, the 
QRET-based kinase assay was achieved in a single-label approach. 
Moreover, the data indicated that the assay could potentially be applied to 
other enzymes, with the correct substrate peptide and antibody for detection. 
However, this would need the expensive and time consuming production of 
a Eu3+-labeled peptide for every enzyme. Also, as in all antibody-based 
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a Eu3+-labeled peptide for every enzyme. Also, as in all antibody-based 




detection systems, the extension of the approach would be limited by the 
availability of suitable PTM targeting antibodies. In this sense, this approach 
does not represent the best system for a universal PTM enzymatic assay.  
 
II  The current HTS methods for PTM monitoring face detection limitations, 
including antibody dependency, dual-labeling, and so forth, which constrains 
their applicability to other complex PTMs. Based on publication I, the 
peptide-break technology was developed using QRET in an antibody-free 
system and a peptide-peptide binding approach following the LZ concept. Its 
key benefit relies on its simplicity and versatility, as a unique detection Eu3+-
peptide was used for assaying different PTMs. The main challenge with this 
was for the substrate peptide design, as the enzyme consensus sequence had 
to be adapted to the LZ concept for dimerization. Despite this limitation, the 
peptide-break technology was developed for a variety of enzymes for 
phosphorylation, dephosphorylation, deacetylation, and citrullination 
without the need for antibodies or enzyme reporters. 
 
III  In this article, the peptide-break technology was simplified and optimized to 
increase the freedom of substrate peptide selection. The peptide dimerization 
was based on electrostatic interactions between oppositely charged peptides. 
In the system, no specific residues in certain positions nor structural 
conformations were needed for dimerization, but the peptide net charge was 
crucial. This feature provided freedom to modify the peptide length and 
sequence without losing the required affinity or assay window. The peptide-
break technology with charged peptides was optimized using PKA- and 
PIM-mediated phosphorylation assays, and further developed for lysine 
deacetylation, and arginine citrullination assays. The simplified and 
expanded peptide-break technology can potentially be applied to a variety of 
PTMs by simply introducing an enzyme-specific sequence to the charged 
substrate peptide. 
 
IV  In this article, the peptide-break technology was applied to a QRET-based 
thermal shift assay for dephosphorylation and deacetylation. In a standard 
peptide-break assay, micromolar peptide concentrations force peptide 
dimerization independent of the PTM presence. However, applying 
increasing temperature to that system induced dimer disruption yielding S/B 
ratios > 4 for deacetylation and > 20 for dephosphorylation assays. The 
peptide-break thermal shift assay allows the use of high peptide 
concentrations needed in assays for low affinity enzymes with and low 
activity enzymes. The method can be used with micromolar concentrations 
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of substrate peptides and detect nanomolar concentrations of the post-
translationally modified peptide. The approach was demonstrated for two 
hydrolases but could potentially be applied to other targets. 
 
As new targets are emerging, new HTS technologies for the primary screening 
phase are in demand. The QRET-based peptide-break technology developed in 
these studies aimed to provide a versatile biochemical assay adaptable to 
challenging PTMs. Even though the presented data was limited to small PTMs, the 
groundwork presented here suggests the technology could be potentially applicable 
to other PTM types, e.g., glycosylation, and perhaps to the simultaneous assaying 
of multiple enzyme targets. The path from developing a novel HTS technology to 
launching a robust commercial kit was beyond the scope of this doctoral work, but 
we truly expect that the method can be used by the scientific community within 
academia as well as to the pharmaceutical industry.  
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AA amino acid  
Acetyl CoA acetyl coenzyme A 
ADP adenosine diphosphate 
ALPHA amplified luminescent proximity homogeneous assay 
APP β-amyloid precursor protein 
ATP adenosine triphosphate  
Aβ amyloid β-peptide   
BACE1 β-amyloid precursor protein cleaving enzyme 
bZIP basic-region leucine zipper 
CCD charge-coupled device 
CD circular dichroism 
CHEF chelation-enhanced fluorescence 
DELFIA dissociation-enhanced lanthanide fluorescence immunoassay 
DNA deoxyribonucleic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ER endoplasmic reticulum 
EZH2 enhancer of zeste homolog 2 
FI fluorescence intensity 
FP fluorescence polarization 
FRET fluorescence resonance energy transfer 
GEF guanidine nucleotide exchange factor 
GFP green fluorescence protein 
GPI glycosylphosphatidylinositol 
Grb2 growth factor receptor-bound protein 2 
HDAC histone deacetylase 
HER2 human epidermal growth factor receptor 2 
HPLC high performance liquid chromatography 
HTS high throughput screening 
ITC isothermal titration calorimetry 
KATs lysine acetyltransferases 
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KDACs lysine deacetyltransferases 
LMC3+ lewis metal chelate 
Ln3+ lanthanide 
LOD limit-of-detection 
LZ leucine zipper 
MAPK mitogen-activated protein kinase 
MOA mechanism of action 
MRE mean residue ellipticity 
MS mass spectrometry 
NATs Nt-acetyltransferases 
Nt N-terminal 
OGTs O-GlcNAc glycotransferases 
PAINS pan-assay interference compounds 
PDK1 phosphoinositide-dependent kinase-1 
PH phosphocellulose 
PhS phosphosensor 
PI3K phosphatidylinositol 3-kinase 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PIP3 phosphatidylinositol (3,4,5)-trisphosphate 
PKA protein kinase A  
PKC protein kinase C 
PKIS published kinase inhibitor set 
PPIs protein-protein interactions 
PTEN phosphatase and tensin homolog 
PTM post-translational modification  
PTPs protein tyrosine phosphatases 
pTyr phosphorylated tyrosine 
QRET quenching resonance energy transfer 
RT room temperature 
RTKs receptor tyrosine kinases 
SA streptavidin 
SAR structure-activity relationship 
SH2 Src homology 2 
Sox sulfonamide-oxine 
SPA scintillation proximity assay 
S/B signal-to-background 
TEAA triethylammonium acetate  
TRF time-resolved fluorescence 
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